{ "ProductData": { "ID": "CPS_000141", "ProductType": "Others", "BrandName": "FCAL", "ProductNameAddition": "fCAL turbo", "RegulatoryDisclaimer1": "For in vitro diagnostic use.", "DisclaimerGroup1": "IVD", "RegulatoryDisclaimer2": null, "DisclaimerGroup2": null, "RegulatoryDisclaimer3": null, "SampleType": [ "Feces" ], "LicenseDisclaimers": [ ], "RelatedLinks": "", "Clone": "", "ControlTissue": [ "" ], "ISOtypes": "", "Species": [ "" ], "StainLocalization": [ "" ], "ProductNameGlobal": "FCAL" }, "ProductImageDetails": { "ImagePath": "", "ImageType": "Image main" }, "Product2Taxonomy": { "Product2TaxonomyReferences": [ { "StructureSystemIdentifier": "Product_Grouping", "StructureSystemName": "Product Grouping", "NodeID": "01-0865", "StructureNodeStatus": "Active", "NodeName": "cobas fCAL" }, { "StructureSystemIdentifier": "OWP_Product_Types", "StructureSystemName": "Product Types", "NodeID": "20-000-00", "StructureNodeStatus": "Active", "NodeName": "Assays Reagents and Strips" }, { "StructureSystemIdentifier": "Lab_Type", "StructureSystemName": "Lab Types", "NodeID": "050-00", "StructureNodeStatus": "Active", "NodeName": "Core Lab" }, { "StructureSystemIdentifier": "Disease_Areas", "StructureSystemName": "Disease Areas", "NodeID": "21-00-00", "StructureNodeStatus": "Active", "NodeName": "Inflammation" }, { "StructureSystemIdentifier": "Product_Solutions", "StructureSystemName": "Product Solutions", "NodeID": "020", "StructureNodeStatus": "Active", "NodeName": "Clinical Chemistry" }, { "StructureSystemIdentifier": "Applications", "StructureSystemName": "Applications", "NodeID": "99-00-00", "StructureNodeStatus": "Inactive", "NodeName": "" }, { "StructureSystemIdentifier": "OWP_Techniques", "StructureSystemName": "Techniques", "NodeID": "999-00", "StructureNodeStatus": "Inactive", "NodeName": "" }, { "StructureSystemIdentifier": "OWP_Family", "StructureSystemName": "Product Families", "NodeID": "999", "StructureNodeStatus": "Active", "NodeName": "NOT APPLICABLE" }, { "StructureSystemIdentifier": "Pathogens", "StructureSystemName": "Pathogens", "NodeID": "99-00-00", "StructureNodeStatus": "Inactive", "NodeName": "" }, { "StructureSystemIdentifier": "Health_Topics", "StructureSystemName": "Health Topics", "NodeID": "13-00-00", "StructureNodeStatus": "Active", "NodeName": "Gastroenterology" }, { "StructureSystemIdentifier": "Indications", "StructureSystemName": "Indications", "NodeID": "101", "StructureNodeStatus": "Active", "NodeName": "Inflammation" } ] }, "Product2Materials": { "P2MaterialReferences": [ { "MaterialNum": "08910367190", "MaterialDescription": "fCAL, 200T, cobas c pack green, PCh", "RegisteredProductName": "FCAL", "GTIN": "04260714340007", "ProductCategoryText": "Reagents, kits", "OldMaterialNumber": "", "PackSizePIM360": "200 tests", "PackSizeDescPIM360": "cobas c 303/503", "MaterialAnnotation": "", "ReadyForUse": "true", "OrderInformation": "" }, { "MaterialNum": "08910332190", "MaterialDescription": "fCAL, 200T, cobas c 501/502, PCh", "RegisteredProductName": "FCAL", "GTIN": "07613336169926", "ProductCategoryText": "Reagents, kits", "OldMaterialNumber": "", "PackSizePIM360": "200 tests", "PackSizeDescPIM360": "cobas c 501/502", "MaterialAnnotation": "", "ReadyForUse": "true", "OrderInformation": "" } ] }, "Product2Products": { "Product2ProductReference": [ { "ProductID": "INS_338", "BrandName": "cobas® c 501 module", "ProductNameAddition": "", "ReferenceType": "Instrument", "Classification": [ { "IdentifierofStructureSystem": "1", "NameofStructureSystem": "GPCH", "StructureNodeID": "309", "StructureGroupPath": "ClinChem fully automated->Systems / Digital Products->cobas c systems->cobas c 501", "StructureGroupName": "cobas c 501", "StructureNodeStatus": "Active" }, { "IdentifierofStructureSystem": "OWP_Product_Types", "NameofStructureSystem": "Product Types", "StructureNodeID": "10-000-00", "StructureGroupPath": "Analyzer Instruments and Systems", "StructureGroupName": "Analyzer Instruments and Systems", "StructureNodeStatus": "Active" }, { "IdentifierofStructureSystem": "Lab_Type", "NameofStructureSystem": "Lab Types", "StructureNodeID": "050-00", "StructureGroupPath": "Core Lab", "StructureGroupName": "Core Lab", "StructureNodeStatus": "Active" }, { "IdentifierofStructureSystem": "Product_Solutions", "NameofStructureSystem": "Product Solutions", "StructureNodeID": "020", "StructureGroupPath": "Clinical Chemistry", "StructureGroupName": "Clinical Chemistry", "StructureNodeStatus": "Active" }, { "IdentifierofStructureSystem": "Applications", "NameofStructureSystem": "Applications", "StructureNodeID": "99-00-00", "StructureGroupPath": "", "StructureGroupName": "", "StructureNodeStatus": "Inactive" }, { "IdentifierofStructureSystem": "OWP_Techniques", "NameofStructureSystem": "Techniques", "StructureNodeID": "999-00", "StructureGroupPath": "", "StructureGroupName": "", "StructureNodeStatus": "Inactive" }, { "IdentifierofStructureSystem": "Disease_Areas", "NameofStructureSystem": "Disease Areas", "StructureNodeID": "99-00-00", "StructureGroupPath": "", "StructureGroupName": "", "StructureNodeStatus": "Inactive" }, { "IdentifierofStructureSystem": "Pathogens", "NameofStructureSystem": "Pathogens", "StructureNodeID": "99-00-00", "StructureGroupPath": "", "StructureGroupName": "", "StructureNodeStatus": "Inactive" }, { "IdentifierofStructureSystem": "Health_Topics", "NameofStructureSystem": "Health Topics", "StructureNodeID": "99-00-00", "StructureGroupPath": "", "StructureGroupName": "", "StructureNodeStatus": "Inactive" }, { "IdentifierofStructureSystem": "OWP_Family", "NameofStructureSystem": "Product Families", "StructureNodeID": "614", "StructureGroupPath": "cobas c", "StructureGroupName": "cobas c", "StructureNodeStatus": "Active" }, { "IdentifierofStructureSystem": "OWP_Family", "NameofStructureSystem": "Product Families", "StructureNodeID": "679", "StructureGroupPath": "cobas 6000", "StructureGroupName": "cobas 6000", "StructureNodeStatus": "Active" } ] }, { "ProductID": "INS_2113", "BrandName": "cobas® c 502 module", "ProductNameAddition": "", "ReferenceType": "Instrument", "Classification": [ { "IdentifierofStructureSystem": "1", "NameofStructureSystem": "GPCH", "StructureNodeID": "2324", "StructureGroupPath": "ClinChem fully automated->Systems / Digital Products->cobas c systems->cobas c 502", "StructureGroupName": "cobas c 502", "StructureNodeStatus": "Active" }, { "IdentifierofStructureSystem": "OWP_Product_Types", "NameofStructureSystem": "Product Types", "StructureNodeID": "10-000-00", "StructureGroupPath": "Analyzer Instruments and Systems", "StructureGroupName": "Analyzer Instruments and Systems", "StructureNodeStatus": "Active" }, { "IdentifierofStructureSystem": "Lab_Type", "NameofStructureSystem": "Lab Types", "StructureNodeID": "050-00", "StructureGroupPath": "Core Lab", "StructureGroupName": "Core Lab", "StructureNodeStatus": "Active" }, { "IdentifierofStructureSystem": "Product_Solutions", "NameofStructureSystem": "Product Solutions", "StructureNodeID": "020", "StructureGroupPath": "Clinical Chemistry", "StructureGroupName": "Clinical Chemistry", "StructureNodeStatus": "Active" }, { "IdentifierofStructureSystem": "Applications", "NameofStructureSystem": "Applications", "StructureNodeID": "99-00-00", "StructureGroupPath": "", "StructureGroupName": "", "StructureNodeStatus": "Inactive" }, { "IdentifierofStructureSystem": "OWP_Techniques", "NameofStructureSystem": "Techniques", "StructureNodeID": "999-00", "StructureGroupPath": "", "StructureGroupName": "", "StructureNodeStatus": "Inactive" }, { "IdentifierofStructureSystem": "Disease_Areas", "NameofStructureSystem": "Disease Areas", "StructureNodeID": "99-00-00", "StructureGroupPath": "", "StructureGroupName": "", "StructureNodeStatus": "Inactive" }, { "IdentifierofStructureSystem": "Pathogens", "NameofStructureSystem": "Pathogens", "StructureNodeID": "99-00-00", "StructureGroupPath": "", "StructureGroupName": "", "StructureNodeStatus": "Inactive" }, { "IdentifierofStructureSystem": "Health_Topics", "NameofStructureSystem": "Health Topics", "StructureNodeID": "99-00-00", "StructureGroupPath": "", "StructureGroupName": "", "StructureNodeStatus": "Inactive" }, { "IdentifierofStructureSystem": "OWP_Family", "NameofStructureSystem": "Product Families", "StructureNodeID": "614", "StructureGroupPath": "cobas c", "StructureGroupName": "cobas c", "StructureNodeStatus": "Active" } ] }, { "ProductID": "INS_6347", "BrandName": "cobas® c 303 analytical unit", "ProductNameAddition": "", "ReferenceType": "Instrument", "Classification": [ { "IdentifierofStructureSystem": "1", "NameofStructureSystem": "GPCH", "StructureNodeID": "9493", "StructureGroupPath": "ClinChem fully automated->Systems / Digital Products->cobas c systems->cobas c 303", "StructureGroupName": "cobas c 303", "StructureNodeStatus": "Active" }, { "IdentifierofStructureSystem": "OWP_Product_Types", "NameofStructureSystem": "Product Types", "StructureNodeID": "10-000-00", "StructureGroupPath": "Analyzer Instruments and Systems", "StructureGroupName": "Analyzer Instruments and Systems", "StructureNodeStatus": "Active" }, { "IdentifierofStructureSystem": "Lab_Type", "NameofStructureSystem": "Lab Types", "StructureNodeID": "050-00", "StructureGroupPath": "Core Lab", "StructureGroupName": "Core Lab", "StructureNodeStatus": "Active" }, { "IdentifierofStructureSystem": "Product_Solutions", "NameofStructureSystem": "Product Solutions", "StructureNodeID": "020", "StructureGroupPath": "Clinical Chemistry", "StructureGroupName": "Clinical Chemistry", "StructureNodeStatus": "Active" }, { "IdentifierofStructureSystem": "Applications", "NameofStructureSystem": "Applications", "StructureNodeID": "99-00-00", "StructureGroupPath": "", "StructureGroupName": "", "StructureNodeStatus": "Inactive" }, { "IdentifierofStructureSystem": "OWP_Techniques", "NameofStructureSystem": "Techniques", "StructureNodeID": "999-00", "StructureGroupPath": "", "StructureGroupName": "", "StructureNodeStatus": "Inactive" }, { "IdentifierofStructureSystem": "Disease_Areas", "NameofStructureSystem": "Disease Areas", "StructureNodeID": "99-00-00", "StructureGroupPath": "", "StructureGroupName": "", "StructureNodeStatus": "Inactive" }, { "IdentifierofStructureSystem": "Pathogens", "NameofStructureSystem": "Pathogens", "StructureNodeID": "99-00-00", "StructureGroupPath": "", "StructureGroupName": "", "StructureNodeStatus": "Inactive" }, { "IdentifierofStructureSystem": "Health_Topics", "NameofStructureSystem": "Health Topics", "StructureNodeID": "99-00-00", "StructureGroupPath": "", "StructureGroupName": "", "StructureNodeStatus": "Inactive" }, { "IdentifierofStructureSystem": "OWP_Family", "NameofStructureSystem": "Product Families", "StructureNodeID": "614", "StructureGroupPath": "cobas c", "StructureGroupName": "cobas c", "StructureNodeStatus": "Active" } ] } ] }, "ProductSpec": [ { "ProductSpecVariant": { "MetaData": { "DocumentMaterialNumber": "0108910367190c503", "ProductName": "FCAL", "ProductLongName": "fCAL turbo", "Language": "en", "DocumentVersion": "1", "DocumentObjectID": "FF00000005206D0E", "DocumentOriginID": "FF000000050BA80E", "MaterialNumbers": [ "08910367190" ], "InstrumentReferences": [ { "ID": "8481", "BrandName": "cobas c 503" } ], "DisclaimerText": "Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative." }, "Chapters": [ { "Name": "IntendedUse", "Value": "

Intended use

The fCAL turbo is an automated in vitro diagnostic test for the quantitative determination of calprotectin in human stool specimens intended as an aid in the assessment of intestinal mucosal inflammation

LREFNilsen T et al.: J Clin Lab Anal 2017 ; 31(4). doi: 10.1002/jcla.22061
,
LREFMandic-Havelka A et al.: Clin Lab. 2017 ; 63(5):907-913.
,
LREFNoebauer B et al. : Biochem Med (Zagreb) 2017 ; 27(3):030710.
. The assay results can be used as an aid to diagnosis in distinguishing organic, inflammatory disease of the gastrointestinal tract (inflammatory bowel disease, IBD, specifically Crohn’s disease (CD) or ulcerative colitis (UC)) from functional disease (irritable bowel syndrome, IBS)
LREFFagerhol MK: Lancet 2000; 356, 1783-4.
,
LREFTibble JA et al.: Gut 2000; 47, 506-13.
,
LREFTibble JA, Sigthorsson G, Foster R et al. Gastroenterol 2002;123(2):450-460
,
LREFJahnsen J et al.: Tidsskr Nor Legeforen 2009; 129(8), 743-5.
,
LREFManz M. et al.: BMC Gastroenterology 2012; 12, 5.
,
LREFPavlidis P, Chedgy FJ, Tibble JA Scand J Gastroenterol. 2013;48(9):1048-54
,
LREFKonikoff MR, Denson LA. Inflamm Bowel Dis. 2006;12(6):524-34
, in patients with chronic abdominal pain and as an aid to IBD disease monitoring
LREFKonikoff MR, Denson LA. Inflamm Bowel Dis. 2006;12(6):524-34
,
LREFLin et al.: Inflamm Bowel Dis 2014; 20: 1407-15.
,
LREFLobatón T et al.: J Crohns Colitis 2013, 641-51.
,
LREFLobatón T et al.: Inflamm Bowel Dis 2013; 19(5), 1034-42.
,
LREFWright et al.: Gastroenterology 2015; 148(5), 938-947.
,
LREFNaismith GD et al.: J Crohns Colitis 2014; 8, 1022-9.
,
LREFFerreiro-Iglesias R et al.: Scand J Gastroenterol 2015, 23, 1-6.
,
LREFFerreiro-Iglesias R1 et al. : J Clin Gastroenterol 2015; 50(2),147-51.
,
LREFGuardiola J. et al. Clinical Gastroenterology & Hepatology 2014; 12(11) 1865-70.
,
LREFLasson A et al.: United European Gastroenterol J 2015, 3(1) 72-9.
,
LREFBressler B et al.: Can J Gastroenterol Hepatol 2015, 29(7), 369-72.
,
LREFPeyrin-BL et al.: Am J Gastroenterol 2015, 110, 1324-38.
,
LREFRicciuto A et al.: Crit Rev Clin Lab Sci. 2019; 56(5):307-320.
. For laboratory use only.

", "Language": "en" }, { "Name": "TestPrinciple", "Value": "

Test principle

The fCAL turbo test is a particle enhanced turbidimetric immunoassay (PETIA), which allows for automated quantification of calprotectin in fecal extracts on cobas c systems. Fecal samples are extracted with extraction buffer using the CALEX® Cap extraction device and applied at a final dilution of 1:500. The extracts are incubated with reaction buffer and mixed with polystyrene nanoparticles coated with calprotectin-specific antibodies (immunoparticles). Calprotectin available in the sample mediates immunoparticle agglutination. Sample turbidity, measured by light absorbance, increases with calprotectin-immunoparticle complex formation and is proportional to calprotectin concentration. The detected light absorbance allows quantification of calprotectin concentration via interpolation on an established calibration curve.

", "Language": "en" }, { "Name": "MeasuringRange", "Value": "

Limits and ranges

The measuring range for the fCAL turbo assay on the cobas c 503 analyzers is 30‑2000 µg/g. Samples > 2000 µg/g will be diluted automatically (1:10) by the analyzer, further extending the range to 30‑10000 µg/g.

", "Language": "en" }, { "Name": "ExpectedValues", "Value": "

Interpretation of results

Distinguishing organic disease from functional gastrointestinal disease

Determination of fecal calprotectin levels can be used as a reliable and simple aid in distinguishing organic from functional gastrointestinal diseases

LREFFagerhol MK: Lancet 2000; 356, 1783-4.
,
LREFTibble JA et al.: Gut 2000; 47, 506-13.
,
LREFTibble JA, Sigthorsson G, Foster R et al. Gastroenterol 2002;123(2):450-460
,
LREFJahnsen J et al.: Tidsskr Nor Legeforen 2009; 129(8), 743-5.
,
LREFManz M. et al.: BMC Gastroenterology 2012; 12, 5.
,
LREFPavlidis P, Chedgy FJ, Tibble JA Scand J Gastroenterol. 2013;48(9):1048-54
,
LREFKonikoff MR, Denson LA. Inflamm Bowel Dis. 2006;12(6):524-34
. BÜHLMANN recommends applying the following cut‑off values:

Clinical thresholds

Calprotectin concentration

Interpretation

Follow-up

< 80 µg/g

normal

none

80‑160 µg/g

gray-zone/borderline

follow-up within 4‑6 weeks

> 160 µg/g

elevated

repeats as needed

Table 1: fCAL turbo diagnostic ranges.

The result categories are based on data from clinical studies performed by BÜHLMANN and are BÜHLMANN’s recommendations. All test results should be interpreted in conjunction with information available from the patient’s clinical symptoms, medical history, and other clinical and laboratory findings:

Calprotectin values < 80 μg/g
Fecal calprotectin values < 80 µg/g are not indicative of active inflammation in the gastrointestinal tract. Patients with low calprotectin levels are not likely to be in need of invasive procedures to determine the inflammation cause

LREFFagerhol MK: Lancet 2000; 356, 1783-4.
.

Calprotectin values between and equal to 80 and 160 μg/g
Mid‑fecal calprotectin levels between and equal to 80 and 160 µg/g, also called gray‑zone levels, are not directly indicative of an active inflammation requiring immediate follow‑up with invasive testing. However, the presence of inflammation cannot be excluded. Re‑evaluation of fecal calprotectin levels after 4-6 weeks is recommended to determine the inflammatory status.

Calprotectin values > 160 μg/g
Fecal calprotectin values > 160 µg/g are indicative of neutrophil infiltrate in the gastrointestinal tract; therefore, this may signal the presence of active inflammatory disease. Appropriate further investigative procedures by specialists are suggested to achieve an overall clinical diagnosis.

", "Language": "en" }, { "Name": "LimitationInterference", "Value": "

Limitations

• Test results should be interpreted in conjunction with information available from clinical assessment of the patient and other diagnostic procedures.
• For IBD disease monitoring, multiple fecal calprotectin measurements performed at up to 4 weeks intervals have been suggested to have best diagnostic accuracy in predicting clinical relapse in patients

LREFMolander P et al.: Journal of Crohn's and Colitis 2015, 33-40.
,
LREFDe Vos M et al.: Inflamm Bowel Dis. 2013; 19, 2111-2117.
.
• Intake of non‑steroidal anti‑inflammatory drugs (NSAID) may lead to elevated fecal calprotectin levels.
• Results may not be clinically applicable to children less than 4 years of age who have mildly increased fecal calprotectin levels
LREFFagerberg UL et al.: J Pediatr Gastroenterol Nutr 2005; 40, 450-5.
,
LREFLi F. et al.: PLoS ONE 10(3) (2015).
,
LREFZhu Q. et al. PLoS ONE 11 (3) (2016).
,
LREFPeura S. et al.: Scand J Clin Lab Invest 2018; 78(1-2): 120-124.
.

Special wash programming required by the instrument manufacturer:
The manufacturer of the cobas c systems considers the use of special wash steps as mandatory when certain test combinations are run together on cobas c systems. All special wash programming necessary for avoiding carry-over is available via the cobas link. The latest version of the carry‑over evasion list can be found with the NaOHD/SMS/SCCS Method Sheet provided by the instrument manufacturer. For further instructions, refer to the operator’s manual.

", "Language": "en" }, { "Name": "OrderInformation", "Value": "

OrderInformation (CC Reagents - cobas + Integra)

Order information

Analyzer(s) on which cobas c pack(s) can be used

08910367190

fCAL turbo (200 tests)

System‑ID 2149 001

cobas c 503

Materials required (but not provided):

08910499190

fCAL Calibrator Set
fCAL Calibrator 1 (1 x 1 mL)
fCAL Calibrator 2 (1 x 1 mL)
fCAL Calibrator 3 (1 x 1 mL)
fCAL Calibrator 4 (1 x 1 mL)
fCAL Calibrator 5 (1 x 1 mL)
fCAL Calibrator 6 (1 x 1 mL)

Code 20719
Code 20720
Code 20721
Code 20722
Code 20723
Code 20724

08910502190

fCAL Control Set 
fCAL Control Level I  (3 x 1 mL)
fCAL Control Level II  (3 x 1 mL)


Code 20167
Code 20168

08910987001

CALEX® Cap (500 pcs)

", "Language": "en" }, { "Name": "SystemInformation", "Value": "

System information

FCAL: ACN 21490

", "Language": "en" }, { "Name": "Handling", "Value": "

Reagent handling

Ready for use

Loading of reagents

The reagents supplied are ready to use. Mix gently before loading onto the instrument. Avoid bubble formation.

", "Language": "en" }, { "Name": "TestDefinition", "Value": "

Application for fecal extracts

Test definition

Reporting time

10 min

Wavelength (sub/main)

800/546 nm

Reagent pipetting

Diluent (H2O)

R1

100 µL

R3

16 µL

Sample volumes

Sample

Sample dilution

Sample

Diluent (H2O)

Normal

8 µL

Decreased

8 µL

8 µL

72 µL

Increased

8 µL

", "Language": "en" }, { "Name": "StorageStability", "Value": "

Storage and stability

fCAL turbo

Shelf life at 2‑8 °C:

See expiration date on cobas c pack label.

On‑board in use and refrigerated on the analyzer:

store for up to 12 weeks at 5‑15 °C

Do not freeze reagents!

", "Language": "en" }, { "Name": "Calibration", "Value": "

Calibration

Calibrators

S1: fCAL Calibrator 1

S2: fCAL Calibrator 2

S3: fCAL Calibrator 3

S4: fCAL Calibrator 4

S5: fCAL Calibrator 5

S6: fCAL Calibrator 6

Apply the lot-specific fCAL Calibrator values for the 6-point calibration curve:

Calibration mode

Spline

Calibration frequency

Full calibration
• after reagent lot change
• after 9 weeks on‑board the analyzer
• after 9 weeks when using a single reagent lot
• as required following quality control procedures

To generate a reproducible calibration curve, equilibrate reagents R1 and R3 to the storage temperature of the analyzer by loading the cobas c pack at least 1 hour before calibration curve establishment. Keep calibrators at room temperature for at least 30 min before starting analysis. The calibration on cobas c 503 analyzers is performed in duplicate.

", "Language": "en" }, { "Name": "Limitations", "Value": "

Clinical evaluation

The clinical evaluation of fCAL turbo was assessed on the Master System cobas c 501 analyzer. The results are also considered applicable to cobas c 503 analyzer.

The ability of the fCAL turbo to discriminate between patients with IBD and other non-inflammatory GI disorders, including IBS, was evaluated using clinical samples collected from 295 patients and extracted using the CALEX® Cap device. One hundred and twenty seven (127) patients had a final diagnosis of IBD (Crohn’s disease, ulcerative colitis or indeterminate colitis), 103 patients suffered from IBS and 65 patients presented with abdominal pain and/or diarrhea, or other GI-related non-inflammatory conditions. Final diagnosis was supported by endoscopic as well as other clinical findings.

The optimal cut‑off combination for these patient pools could be defined by ROC analysis at 80 µg/g and 160 µg/g calprotectin (table 3 and 5), which is slightly more stringent than a combination of a more sensitive lower cut off of 50 µg/g with lower performance in specificity, and an upper cut off 200 µg/g with slightly lower sensitivity (table 4 and 6).

Final
diagnosis

Distribution of patients results in numbers (%) within fCAL turbo diagnostic ranges

< 80 μg/g

80‑160 μg/g

> 160 μg/g

Total

IBD

11 (8.7 %)

8 (6.3 %)

108 (85 %)

127 (100 %)

IBS

75 (72.8 %)

11 (10.7 %)

17 (16.5 %)

103 (100 %)

Other GI

42 (64.6 %)

8 (12.3 %)

15 (23.1 %)

65 (100 %)

Table 2: Distribution of patients results within fCAL turbo diagnostic ranges

IBD vs. non‑IBD

Clinical decision point

80 μg/g

160 μg/g

Sensitivity (95 % CI)

91.3 % (85.0 %, 95.6 %)

85.0 % (77.6 %, 90.7 %)

Specificity (95 % CI)

69.6 % (62.1 %, 76.5 %)

81.0 % (74.2 %, 86.6 %)

PPV (95 % CI)

69.5 % (61.9 %, 76.3 %)

77.1 % (69.3 %, 83.8 %)

NPV (95 % CI)

91.4 % (85.1 %, 95.6 %)

87.7 % (81.5 %, 92.5 %)

ROC AUC (95 % CI)

0.912 (0.878, 0.946)

Table 3: Clinical performance characteristics of the fCAL turbo in discriminating IBD from non‑IBD − IBS and other GI‑related disorders, at 80 μg/g and 160 μg/g clinical decision points

IBD vs. non‑IBD

Clinical decision point

50 μg/g

200 μg/g

Sensitivity (95 % CI)

94.5 % (89.0 %, 97.8 %)

80.3 % (72.3 %, 86.8 %)

Specificity (95 % CI)

62.5 % (54.7 %, 69.8 %)

85.7 % (79.5 %, 90.6 %)

PPV (95 % CI)

65.6 % (58.2 %, 72.4 %)

81.0 % (73.0 %, 87.4 %)

NPV (95 % CI)

93.8 % (87.5 %, 97.5 %)

85.2 % (78.9 %, 90.2 %)

Table 4: Clinical performance characteristics of the fCAL turbo in discriminating IBD from non‑IBD – IBS and other GI‑related disorders, at 50 µg/g and 200 µg/g clinical decision points

IBD vs. IBS

Clinical decision point

80 μg/g

160 μg/g

Sensitivity (95 % CI)

91.3 % (85.0 %, 95.6 %)

85.0 % (77.6 %, 90.7 %)

Specificity (95 % CI)

72.8 % (63.2 %, 81.1 %)

83.5 % (74.9 %, 90.1 %)

PPV (95 % CI)

80.6 % (73.1 %, 86.7 %)

86.4 % (79.1 %, 91.9 %)

NPV (95 % CI)

87.2 % (78.3 %, 93.4 %)

81.9 % (73.2 %, 88.7 %)

ROC AUC (95 % CI)

0.925 (0.892, 0.958)

Table 5: Clinical performance characteristics of the fCAL turbo in discriminating IBD from IBS at 80 μg/g and 160 μg/g clinical decision points

IBD vs. IBS

Clinical decision point

50 μg/g

200 μg/g

Sensitivity (95 % CI)

94.5 % (89.0 %, 97.8 %)

80.3 % (72.3 %, 86.8 %)

Specificity (95 % CI)

67.0 % (57.0 %, 75.9 %)

88.3 % (80.5 %, 93.8 %)

PPV (95 % CI)

77.9 % (70.5 %, 84.2 %)

89.5 % (82.3 %, 94.4 %)

NPV (95 % CI)

90.8 % (81.9 %, 96.2 %)

78.4 % (69.9 %, 85.5 %)

Table 6: Clinical performance characteristics of the fCAL turbo in discriminating IBD from IBS at 50 µg/g and 200 µg/g clinical decision points

CI − confidence interval
PPV − positive predictive value
NPV − negative predictive value
ROC AUC − area under receiver operating characteristic curve

", "Language": "en" }, { "Name": "PerformanceData", "Value": "", "Language": "en" }, { "Name": "Precision", "Value": "

Specific performance data

The presented performance characteristics have been established on the cobas c 503 analyzer, unless otherwise indicated, and should be considered as representative data. Results obtained in individual laboratories may differ.

For regulatory purposes validation was performed using extracts obtained by manual weighing and extraction. The CALEX® Cap was validated for comparability with the manual extraction method on a cobas c 501 analyzer. Please refer to the CALEX® Cap method sheet for results. Any changes to the directions for use, including special wash programming, may alter the stated performance characteristics of the assay and must be validated prior to implementation by the laboratory.

Method comparison

The method comparison study was performed according to the CLSI guideline EP09-A3. Forty‑five (45) clinical samples were measured on a cobas c 503 analyzer using one lot of fCAL turbo over 1 day in one calibration cycle. Reference values, with a final calprotectin concentration interval of 39.1‑9075.4 μg/g, were established with the fCAL turbo on a cobas c 501 analyzer. Bias was determined using Passing‑Bablok linear regression and Bland‑Altman analysis.

Bland‑Altman analysis

Passing-Bablok regression
analysis

Mean
bias

(95 % CI)

Lower
LoA

(95 % CI)

Upper
LoA

(95 % CI)


Slope

(95 % CI)

Intercept

(95 % CI)

Bias at 80 μg/g

(95 % CI)

Bias at 160 μg/g

(95 % CI)


r

-6.97 % (9.11 %, -4.83 %)

-20.93 % (-24.62 %, -17.25 %)

6.99 % (3.31 %, 10.68 %)

0.9866
(0.9657,
1.005)

-7.276 μg/g (-12.18 μg/g, -5.32 μg/g)

-10.4 %
(-15.8 %, -9.2 %)

-5.9 %
(-8.5 %, -4.9 %)


0.998

Table 9: Method comparison study results, (LoA= Limits of agreement)

Repeatability (within‑run precision): 0.2‑3.6 % CV

Total precision: 1.6‑7.6 % CV

Repeatability and total precision were established according to the CLSI guideline EP05‑A3 using a 5 days x 2 runs x 4 replicates study design using an acceptance criterion of 15 % CV. Six (6) pooled stool specimen extracts with calprotectin concentrations ranging from 49.0‑6657.9 µg/g were tested.

Sample carry-over

The sample carry‑over was established according to the CLSI guideline EP10‑A2. No statistically significant carry‑over with the fCAL turbo test on cobas c 503 instrument was detected.

Limit of Detection (LoD): 6.3 μg/g

The LoD was established according to the CLSI guideline EP17‑A2 and with proportions of false positives (α) less than 5 % and false negatives (β) less than 5 % based on 120 determinations, with 60 blank and 60 low level replicates; and a LoB of 2.6 µg/g.

Limit of Quantitation (LoQ): 13.3 μg/g

The LoQ was established according to the CLSI guideline EP17‑A2, based on 60 determinations and a precision goal of 20 % CV using an acceptance criterion of LoQ ≤ 30 µg/g.

Linearity range: 5.5‑12959.7 μg/g

The linear range of the fCAL turbo was determined according to the CLSI guideline EP06‑A. Samples with a concentration over 2000 μg/g were diluted automatically 1:10 by the analyzer. A maximum deviation from linearity of 10 % was allowed. For values below 75 µg/g an absolute difference of less than 7.5 µg/g was allowed.

The following performance characteristics have been established on the Master System cobas c 501 analyzer. The results are also considered applicable to the cobas c 503 analyzer.

", "Language": "en" }, { "Name": "MethodComparison", "Value": "", "Language": "en" }, { "Name": "Summary", "Value": "", "Language": "en" }, { "Name": "Reagents", "Value": "

Reagents - working solutions

Reagents

Quantity

Preparation

Reaction Buffer (R1)
MOPS buffered saline

25.4 mL

Ready to use

Immunoparticles (R3)
Polystyrene beads coated with avian antibodies against human calprotectin

6.5 mL

Ready to use

R1 is in position B and R3 is in position C. R3 refers to the reagent, which is pipetted at time point R3.

", "Language": "en" }, { "Name": "PrecautionsWarnings", "Value": "

Precautions and warnings

For in vitro diagnostic use.
Exercise the normal precautions required for handling all laboratory reagents.
Disposal of all waste material should be in accordance with local guidelines.
Safety data sheet available for professional user on request.

Product safety labeling follows EU GHS guidance.

Contact phone: all countries: +49-621-7590

This kit contains components classified in accordance with the Regulation (EC) No. 1272/2008: 2‑methyl‑4‑isothiazolin‑3‑one hydrochloride (conc. ≥ 0.0015 %), thus the reagents may cause allergic skin reactions (H317).

The immunoparticles contain potentially infectious substances of animal origin and should be handled in accordance with Good Laboratory Practice (GLP) using appropriate precautions.
• Avoid contact of reagents with the skin, eyes or mucous membranes. If contact does occur, immediately wash with generous amounts of water; otherwise, irritation / burns can occur.
• Immunoparticles R3 contains polystyrene nanoparticles.
• Reagent Immunoparticles R3, once frozen, cannot be used anymore.
• The assay is designed for fecal extract samples prepared using the specific CALEX® Cap devices.
• Please equilibrate reagents, controls, calibrators and samples as described in this method sheet.
• Ensure that samples have no bubbles prior to running the test.
• Evaporation of calibrators and controls on the analyzer could lead to incorrect results. Run the assay immediately after loading the analyzer.

", "Language": "en" }, { "Name": "Caution", "Value": "", "Language": "en" }, { "Name": "QualityControl", "Value": "

Quality control

For quality control, use control materials as listed in the \"Order information\" section.

Validating instrument accuracy after calibration

Run the fCAL Control Set, Level I and Level II, in duplicate, after each new calibration, before running patient fecal sample extracts. Keep controls at room temperature for at least 30 min before starting analysis.

Validating daily runs

Run the fCAL Control Set, Level I and Level II, each day, before running patient fecal sample extracts to validate calibration curve stability. Single measurements of controls are sufficient.

The controls have assigned target values indicated on the control value sheet supplied with each lot of the fCAL Control Set. All control measurements must be within target values indicated on the control value sheet to obtain valid results for patient fecal sample extracts. If the control values are not valid, repeat quality control measurement with fresh controls. If control values remain invalid, recalibrate the instrument. If valid controls values cannot be reproduced after performing the steps described above, contact your local customer support.

Measuring patient samples

Once a calibration curve is established and validated with the quality controls, patient fecal extracts may be measured. Allow patient fecal sample extracts to equilibrate to room temperature for at least 30 minutes before starting analysis. Perform patient fecal extract measurement according to this instruction for use and instrument manual.

", "Language": "en" }, { "Name": "SpecimenPreparation", "Value": "

Specimen collection and preparation

The fCAL turbo is designed for calprotectin quantification in fecal sample extracts. Fecal samples are collected, extracted and diluted to a final concentration of 1:500 using the CALEX® Cap device.

Specimen transport and storage

Stool specimens should be received for processing by the laboratory within 3 days of collection. Stool specimens may be shipped at room temperature or refrigerated. Stool specimens should be refrigerated at 2‑8 °C and extracted within 3 days of receipt at the laboratory. Do not store samples at elevated temperatures.

Stability in CALEX® Cap extracts

For CALEX® Cap extract stability refer to the instruction for use provided with the CALEX® Cap (REF: 08910987 001).

Laboratories are responsible for validating use of alternate storage temperatures/timeframes.

Stool extraction using the CALEX® Cap:

Follow the instruction for use provided with the CALEX® Cap kit. Fecal sample extracts prepared using the CALEX® Cap will have a final dilution of 1:500 and are ready to use.

Important: Centrifuge the CALEX® Cap device for 10 minutes at 1000‑3000 g prior to running the fCAL turbo procedure.

", "Language": "en" } ] } }, { "ProductSpecVariant": { "MetaData": { "DocumentMaterialNumber": "0108910367190c503", "ProductName": "FCAL", "ProductLongName": "fCAL turbo", "Language": "en", "DocumentVersion": "2", "DocumentObjectID": "FF00000005A8840E", "DocumentOriginID": "FF00000005A8840E", "MaterialNumbers": [ "08910367190" ], "InstrumentReferences": [ { "ID": "9493", "BrandName": "cobas c 303" }, { "ID": "8481", "BrandName": "cobas c 503" } ], "DisclaimerText": "Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative." }, "Chapters": [ { "Name": "IntendedUse", "Value": "

Intended use

The fCAL turbo is an automated in vitro diagnostic test for the quantitative determination of calprotectin in human stool specimens intended as an aid in the assessment of intestinal mucosal inflammation

LREFNilsen T et al.: J Clin Lab Anal 2017 ; 31(4). doi: 10.1002/jcla.22061
,
LREFMandic-Havelka A et al.: Clin Lab. 2017 ; 63(5):907-913.
,
LREFNoebauer B et al. : Biochem Med (Zagreb) 2017 ; 27(3):030710.
. The assay results can be used as an aid to diagnosis in distinguishing organic, inflammatory disease of the gastrointestinal tract (inflammatory bowel disease, IBD, specifically Crohn’s disease (CD) or ulcerative colitis (UC)) from functional disease (irritable bowel syndrome, IBS)
LREFFagerhol MK: Lancet 2000; 356, 1783-4.
,
LREFTibble JA et al.: Gut 2000; 47, 506-13.
,
LREFTibble JA, Sigthorsson G, Foster R et al. Gastroenterol 2002;123(2):450-460.
,
LREFJahnsen J et al.: Tidsskr Nor Legeforen 2009; 129(8), 743-5.
,
LREFManz M. et al.: BMC Gastroenterology 2012; 12, 5.
,
LREFPavlidis P, Chedgy FJ, Tibble JA Scand J Gastroenterol. 2013;48(9):1048-54.
,
LREFKonikoff MR, Denson LA. Inflamm Bowel Dis. 2006;12(6):524-34.
, in patients with chronic abdominal pain and as an aid to IBD disease monitoring
LREFKonikoff MR, Denson LA. Inflamm Bowel Dis. 2006;12(6):524-34.
,
LREFLin et al.: Inflamm Bowel Dis 2014; 20: 1407-15.
,
LREFLobatón T et al.: J Crohns Colitis 2013, 641-51.
,
LREFLobatón T et al.: Inflamm Bowel Dis 2013; 19(5), 1034-42.
,
LREFWright et al.: Gastroenterology 2015; 148(5), 938-947.
,
LREFNaismith GD et al.: J Crohns Colitis 2014; 8, 1022-9.
,
LREFFerreiro-Iglesias R et al.: Scand J Gastroenterol 2015, 23, 1-6.
,
LREFFerreiro-Iglesias R1 et al. : J Clin Gastroenterol 2015; 50(2),147-51.
,
LREFGuardiola J. et al. Clinical Gastroenterology & Hepatology 2014; 12(11) 1865-70.
,
LREFLasson A et al.: United European Gastroenterol J 2015, 3(1) 72-9.
,
LREFBressler B et al.: Can J Gastroenterol Hepatol 2015, 29(7), 369-72.
,
LREFPeyrin-BL et al.: Am J Gastroenterol 2015, 110, 1324-38.
,
LREFRicciuto A et al.: Crit Rev Clin Lab Sci. 2019; 56(5):307-320.
. For laboratory use only.

", "Language": "en" }, { "Name": "TestPrinciple", "Value": "

Test principle

The fCAL turbo test is a particle enhanced turbidimetric immunoassay (PETIA), which allows for automated quantification of calprotectin in fecal extracts on cobas c systems. Fecal samples are extracted with extraction buffer using the CALEX® Cap extraction device and applied at a final dilution of 1:500. The extracts are incubated with reaction buffer and mixed with polystyrene nanoparticles coated with calprotectin-specific antibodies (immunoparticles). Calprotectin available in the sample mediates immunoparticle agglutination. Sample turbidity, measured by light absorbance, increases with calprotectin-immunoparticle complex formation and is proportional to calprotectin concentration. The detected light absorbance allows quantification of calprotectin concentration via interpolation on an established calibration curve.

", "Language": "en" }, { "Name": "MeasuringRange", "Value": "

Limits and ranges

The measuring range for the fCAL turbo assay on the cobas c 303 analyzers andcobas c 503 analyzers is 30‑2000 µg/g. Samples > 2000 µg/g will be diluted automatically (1:10) by the analyzer, further extending the range to 30‑10000 µg/g.

", "Language": "en" }, { "Name": "ExpectedValues", "Value": "

Interpretation of results

Distinguishing organic disease from functional gastrointestinal disease

Determination of fecal calprotectin levels can be used as a reliable and simple aid in distinguishing organic from functional gastrointestinal diseases

LREFFagerhol MK: Lancet 2000; 356, 1783-4.
,
LREFTibble JA et al.: Gut 2000; 47, 506-13.
,
LREFTibble JA, Sigthorsson G, Foster R et al. Gastroenterol 2002;123(2):450-460.
,
LREFJahnsen J et al.: Tidsskr Nor Legeforen 2009; 129(8), 743-5.
,
LREFManz M. et al.: BMC Gastroenterology 2012; 12, 5.
,
LREFPavlidis P, Chedgy FJ, Tibble JA Scand J Gastroenterol. 2013;48(9):1048-54.
,
LREFKonikoff MR, Denson LA. Inflamm Bowel Dis. 2006;12(6):524-34.
. BÜHLMANN recommends applying the following cut‑off values:

Clinical thresholds

Calprotectin concentration

Interpretation

Follow-up

< 80 µg/g

normal

none

80‑160 µg/g

gray-zone/borderline

follow-up within 4‑6 weeks

> 160 µg/g

elevated

repeats as needed

Table 1: fCAL turbo diagnostic ranges.

The result categories are based on data from clinical studies performed by BÜHLMANN and are BÜHLMANN’s recommendations. All test results should be interpreted in conjunction with information available from the patient’s clinical symptoms, medical history, and other clinical and laboratory findings:

Calprotectin values < 80 μg/g
Fecal calprotectin values < 80 µg/g are not indicative of active inflammation in the gastrointestinal tract. Patients with low calprotectin levels are not likely to be in need of invasive procedures to determine the inflammation cause

LREFFagerhol MK: Lancet 2000; 356, 1783-4.
.

Calprotectin values between and equal to 80 and 160 μg/g
Mid‑fecal calprotectin levels between and equal to 80 and 160 µg/g, also called gray‑zone levels, are not directly indicative of an active inflammation requiring immediate follow‑up with invasive testing. However, the presence of inflammation cannot be excluded. Re‑evaluation of fecal calprotectin levels after 4-6 weeks is recommended to determine the inflammatory status.

Calprotectin values > 160 μg/g
Fecal calprotectin values > 160 µg/g are indicative of neutrophil infiltrate in the gastrointestinal tract; therefore, this may signal the presence of active inflammatory disease. Appropriate further investigative procedures by specialists are suggested to achieve an overall clinical diagnosis.

", "Language": "en" }, { "Name": "LimitationInterference", "Value": "

Limitations

• Test results should be interpreted in conjunction with information available from clinical assessment of the patient and other diagnostic procedures.
• For IBD disease monitoring, multiple fecal calprotectin measurements performed at up to 4 weeks intervals have been suggested to have best diagnostic accuracy in predicting clinical relapse in patients

LREFMolander P et al.: Journal of Crohn's and Colitis 2015, 33-40.
,
LREFDe Vos M et al.: Inflamm Bowel Dis. 2013; 19, 2111-2117.
.
• Intake of non‑steroidal anti‑inflammatory drugs (NSAID) may lead to elevated fecal calprotectin levels.
• Results may not be clinically applicable to children less than 4 years of age who have mildly increased fecal calprotectin levels
LREFFagerberg UL et al.: J Pediatr Gastroenterol Nutr 2005; 40, 450-5.
,
LREFLi F. et al.: PLoS ONE 10(3) (2015).
,
LREFZhu Q. et al. PLoS ONE 11 (3) (2016).
,
LREFPeura S. et al.: Scand J Clin Lab Invest 2018; 78(1-2): 120-124.
.

Special wash programming required by the instrument manufacturer:
The manufacturer of the cobas c systems considers the use of special wash steps as mandatory when certain test combinations are run together on cobas c systems. All special wash programming necessary for avoiding carry-over is available via the cobas link. The latest version of the carry‑over evasion list can be found with the NaOHD/SMS/SCCS Method Sheet provided by the instrument manufacturer. For further instructions, refer to the operator’s manual.

", "Language": "en" }, { "Name": "OrderInformation", "Value": "

OrderInformation (CC Reagents - cobas + Integra)

Order information

Analyzer(s) on which cobas c pack(s) can be used

08910367190

fCAL turbo (200 tests)

System‑ID 2149 001

cobas c 303, cobas c 503

Materials required (but not provided):

08910499190

fCAL Calibrator Set
fCAL Calibrator 1 (1 x 1 mL)
fCAL Calibrator 2 (1 x 1 mL)
fCAL Calibrator 3 (1 x 1 mL)
fCAL Calibrator 4 (1 x 1 mL)
fCAL Calibrator 5 (1 x 1 mL)
fCAL Calibrator 6 (1 x 1 mL)

Code 20719
Code 20720
Code 20721
Code 20722
Code 20723
Code 20724

08910502190

fCAL Control Set 
fCAL Control Level I  (3 x 1 mL)
fCAL Control Level II  (3 x 1 mL)


Code 20167
Code 20168

08910987001

CALEX® Cap (500 pcs)

", "Language": "en" }, { "Name": "SystemInformation", "Value": "

System information

FCAL: ACN 21490

", "Language": "en" }, { "Name": "Handling", "Value": "

Reagent handling

Ready for use

Loading of reagents

The reagents supplied are ready to use. Mix gently before loading onto the instrument. Avoid bubble formation.

", "Language": "en" }, { "Name": "TestDefinition", "Value": "

Application for fecal extracts

Test definition

Reporting time

10 min

Wavelength (sub/main)

800/546 nm

Reagent pipetting

Diluent (H2O)

R1

100 µL

R3

16 µL

Sample volumes

Sample

Sample dilution

Sample

Diluent (H2O)

Normal

8 µL

Decreased

8 µL

8 µL

72 µL

Increased

8 µL

", "Language": "en" }, { "Name": "StorageStability", "Value": "

Storage and stability

fCAL turbo

Shelf life at 2‑8 °C:

See expiration date on cobas c pack label.

On‑board in use and refrigerated on the analyzer:

store for up to 12 weeks at 5‑15 °C

Do not freeze reagents!

", "Language": "en" }, { "Name": "Calibration", "Value": "

Calibration

Calibrators

S1: fCAL Calibrator 1

S2: fCAL Calibrator 2

S3: fCAL Calibrator 3

S4: fCAL Calibrator 4

S5: fCAL Calibrator 5

S6: fCAL Calibrator 6

Apply the lot-specific fCAL Calibrator values for the 6-point calibration curve:

Calibration mode

Spline

Calibration frequency

Full calibration
• after reagent lot change
• after 9 weeks on‑board of the analyzer
• after 9 weeks when using a single reagent lot
• as required following quality control procedures

To generate a reproducible calibration curve, equilibrate reagents R1 and R3 to the storage temperature of the analyzer by loading the cobas c pack at least 1 hour before calibration curve establishment. Keep calibrators at room temperature for at least 30 min before starting analysis. The calibration on cobas c 303 analyzers andcobas c 503 analyzers is performed in duplicate.

", "Language": "en" }, { "Name": "Limitations", "Value": "

Clinical evaluation

The clinical evaluation of fCAL turbo was assessed on the Master System cobas c 501 analyzer. The results are also considered applicable to cobas c 303 analyzer and cobas c 503 analyzer.

The ability of the fCAL turbo to discriminate between patients with IBD and other non-inflammatory GI disorders, including IBS, was evaluated using clinical samples collected from 295 patients and extracted using the CALEX® Cap. One hundred and twenty seven (127) patients had a final diagnosis of IBD (Crohn’s disease, ulcerative colitis or indeterminate colitis), 103 patients suffered from IBS and 65 patients presented with abdominal pain and/or diarrhea, or other GI-related non-inflammatory conditions. Final diagnosis was supported by endoscopic as well as other clinical findings.

The optimal cut‑off combination for these patient pools could be defined by ROC analysis at 80 µg/g and 160 µg/g calprotectin (table 3 and 5), which is slightly more stringent than a combination of a more sensitive lower cut off of 50 µg/g with lower performance in specificity, and an upper cut off 200 µg/g with slightly lower sensitivity (table 4 and 6).

Final
diagnosis

Distribution of patients results in numbers (%) within fCAL turbo diagnostic ranges

< 80 μg/g

80‑160 μg/g

> 160 μg/g

Total

IBD

11 (8.7 %)

8 (6.3 %)

108 (85 %)

127 (100 %)

IBS

75 (72.8 %)

11 (10.7 %)

17 (16.5 %)

103 (100 %)

Other GI

42 (64.6 %)

8 (12.3 %)

15 (23.1 %)

65 (100 %)

Table 2: Distribution of patients results within fCAL turbo diagnostic ranges

IBD vs. non‑IBD

Clinical decision point

80 μg/g

160 μg/g

Sensitivity (95 % CI)

91.3 % (85.0 %, 95.6 %)

85.0 % (77.6 %, 90.7 %)

Specificity (95 % CI)

69.6 % (62.1 %, 76.5 %)

81.0 % (74.2 %, 86.6 %)

PPV (95 % CI)

69.5 % (61.9 %, 76.3 %)

77.1 % (69.3 %, 83.8 %)

NPV (95 % CI)

91.4 % (85.1 %, 95.6 %)

87.7 % (81.5 %, 92.5 %)

ROC AUC (95 % CI)

0.912 (0.878, 0.946)

Table 3: Clinical performance characteristics of the fCAL turbo in discriminating IBD from non‑IBD − IBS and other GI‑related disorders, at 80 μg/g and 160 μg/g clinical decision points

IBD vs. non‑IBD

Clinical decision point

50 μg/g

200 μg/g

Sensitivity (95 % CI)

94.5 % (89.0 %, 97.8 %)

80.3 % (72.3 %, 86.8 %)

Specificity (95 % CI)

62.5 % (54.7 %, 69.8 %)

85.7 % (79.5 %, 90.6 %)

PPV (95 % CI)

65.6 % (58.2 %, 72.4 %)

81.0 % (73.0 %, 87.4 %)

NPV (95 % CI)

93.8 % (87.5 %, 97.5 %)

85.2 % (78.9 %, 90.2 %)

Table 4: Clinical performance characteristics of the fCAL turbo in discriminating IBD from non‑IBD – IBS and other GI‑related disorders, at 50 µg/g and 200 µg/g clinical decision points

IBD vs. IBS

Clinical decision point

80 μg/g

160 μg/g

Sensitivity (95 % CI)

91.3 % (85.0 %, 95.6 %)

85.0 % (77.6 %, 90.7 %)

Specificity (95 % CI)

72.8 % (63.2 %, 81.1 %)

83.5 % (74.9 %, 90.1 %)

PPV (95 % CI)

80.6 % (73.1 %, 86.7 %)

86.4 % (79.1 %, 91.9 %)

NPV (95 % CI)

87.2 % (78.3 %, 93.4 %)

81.9 % (73.2 %, 88.7 %)

ROC AUC (95 % CI)

0.925 (0.892, 0.958)

Table 5: Clinical performance characteristics of the fCAL turbo in discriminating IBD from IBS at 80 μg/g and 160 μg/g clinical decision points

IBD vs. IBS

Clinical decision point

50 μg/g

200 μg/g

Sensitivity (95 % CI)

94.5 % (89.0 %, 97.8 %)

80.3 % (72.3 %, 86.8 %)

Specificity (95 % CI)

67.0 % (57.0 %, 75.9 %)

88.3 % (80.5 %, 93.8 %)

PPV (95 % CI)

77.9 % (70.5 %, 84.2 %)

89.5 % (82.3 %, 94.4 %)

NPV (95 % CI)

90.8 % (81.9 %, 96.2 %)

78.4 % (69.9 %, 85.5 %)

Table 6: Clinical performance characteristics of the fCAL turbo in discriminating IBD from IBS at 50 µg/g and 200 µg/g clinical decision points

CI − confidence interval
PPV − positive predictive value
NPV − negative predictive value
ROC AUC − area under receiver operating characteristic curve

", "Language": "en" }, { "Name": "PerformanceData", "Value": "", "Language": "en" }, { "Name": "Precision", "Value": "

Specific performance data

The presented performance characteristics have been established on the cobas c 303 analyzer and cobas c 503 analyzer, unless otherwise indicated, and should be considered as representative data. Results obtained in individual laboratories may differ.

For regulatory purposes validation was performed using extracts obtained by manual weighing and extraction. The CALEX® Cap was validated for comparability with the manual extraction method on a cobas c 501 analyzer. Any changes to the directions for use, including special wash programming, may alter the stated performance characteristics of the assay and must be validated prior to implementation by the laboratory.

Method comparison

The method comparison study was performed according to the CLSI guideline EP09-A3. Forty‑five (45) clinical samples were measured on cobas c 503 analyzer and cobas c 303 analyzer using one lot of fCAL turbo over 1 day in one calibration cycle. Reference values, with a final calprotectin concentration interval of 39.1‑9075.4 μg/g, were established with the fCAL turbo on a cobas c 501 analyzer. Bias was determined using Passing‑Bablok linear regression and Bland‑Altman analysis.

Bland‑Altman analysis

Passing-Bablok regression
analysis

Mean
bias

(95 % CI)

Lower
LoA

(95 % CI)

Upper
LoA

(95 % CI)

Slope

(95 % CI)

Intercept

(95 % CI)

Bias at 80 μg/g

(95 % CI)

Bias at 160 μg/g

(95 % CI)

r

-7.0 % (-9.1 %, -4.8 %)

-20.9 % (-24.6 %, -17.3 %)

7.0 % (3.3 %, 10.7 %)

0.9866
(0.9657,
1.005)

-7.28 μg/g (-12.18 μg/g, -5.32 μg/g)

-10.4 %
(-15.8 %, -9.2 %)

-5.9 %
(-8.5 %, -4.9 %)


0.998

Table 9: Summary of Bland‑Altman and Passing‑Bablok regression analyses obtained on cobas c 503 analyzer vs. established reference values on cobas c 501 analyzer (LoA= Limits of agreement)

Bland‑Altman analysis

Passing-Bablok regression
analysis

Mean
bias

(95 % CI)

Lower
LoA

(95 % CI)

Upper
LoA

(95 % CI)

Slope

(95 % CI)

Intercept

(95 % CI)

Bias at 80 μg/g

(95 % CI)

Bias at 160 μg/g

(95 % CI)

r

6.4 % (4.8 %, 7.9 %)

-3.7 % (-6.3 %, -1.0 %)

16.4 % (13.7 %, 19.0 %)

1.075
(1.049,
1.105)

-1.122 μg/g (-5.722 μg/g, 4.137 μg/g)

6.1 %
(1.5 %, 10.7 %)

6.8 %
(4.6 %, 8.7 %)


1.000

Table 10: Summary of Bland‑Altman and Passing‑Bablok regression analyses obtained on cobas c 303 analyzer vs. established reference values on cobas c 501 analyzer (LoA= Limits of agreement)

Repeatability (within‑run precision):

cobas c 303 analyzer: 0.3‑3.0 % CV

cobas c 503 analyzer: 0.2‑3.6 % CV

Total precision:

cobas c 303 analyzer: 1.9‑6.0 % CV

cobas c 503 analyzer: 1.6‑7.6 % CV

Repeatability and total precision were established according to the CLSI guideline EP05‑A3 using a 5 days x 2 runs x 4 replicates study design using an acceptance criterion of 15 % CV. Six (6) pooled stool specimen extracts with calprotectin concentrations ranging from ~50‑6800 µg/g were tested.

Sample carry-over

The sample carry‑over was established according to the CLSI guideline EP10‑A2. No statistically significant carry‑over with the fCAL turbo test on cobas c 303 analyzer and cobas c 503 analyzer was detected.

Limit of Detection (LoD):

cobas c 303 analyzer: 12.9 µg/g

cobas c 503 analyzer: 6.3 μg/g

The LoD was established according to the CLSI guideline EP17‑A2 and with proportions of false positives (α) less than 5 % and false negatives (β) less than 5 % based on 120 determinations, with 60 blank and 60 low level replicates; and LoB of 9.8 µg/g for cobas c 303 analyzer and LoB of 2.6 µg/g for cobas c 503 analyzer.

Limit of Quantitation (LoQ):

cobas c 303 analyzer: 21.2 μg/g

cobas c 503 analyzer: 13.3 μg/g

The LoQ was established according to the CLSI guideline EP17‑A2, based on 60 determinations and a precision goal of 20 % CV using an acceptance criterion of LoQ ≤ 30 µg/g.

Linearity range:

cobas c 303 analyzer: 17.7‑13427 μg/g

cobas c 503 analyzer: 18.7‑12988 μg/g

The linear range of the fCAL turbo was determined according to the CLSI guideline EP06‑A. Samples with a concentration over 2000 μg/g were diluted automatically 1:10 by the analyzer. A maximum deviation from linearity of 10 % was allowed. For values below 75 µg/g an absolute difference of less than 7.5 µg/g was allowed.

The following performance characteristics have been established on the Master System cobas c 501 analyzer. The results are also considered applicable to the cobas c 303 analyzer and cobas c 503 analyzer.

Extraction reproducibility CALEX®Cap: 8.1‑19.7 % CV

The extraction reproducibility was established according to the CLSI guideline EP05‑A3 using a 2 days x 2 operators x 3 CALEX® Cap lots x 2 extractions x 3 replicates study design. Twelve clinical stool specimens, including specimens with solid, semi-solid and liquid consistency, with calprotectin concentrations in the range of 42.7‑3440.0 μg/g, were tested.

", "Language": "en" }, { "Name": "MethodComparison", "Value": "", "Language": "en" }, { "Name": "Summary", "Value": "", "Language": "en" }, { "Name": "Reagents", "Value": "

Reagents - working solutions

Reagents

Quantity

Preparation

Reaction Buffer (R1)
MOPS buffered saline

25.4 mL

Ready to use

Immunoparticles (R3)
Polystyrene beads coated with avian antibodies against human calprotectin

6.5 mL

Ready to use

R1 is in position B and R3 is in position C. R3 refers to the reagent, which is pipetted at time point R3.

", "Language": "en" }, { "Name": "PrecautionsWarnings", "Value": "

Precautions and warnings

For in vitro diagnostic use.
Exercise the normal precautions required for handling all laboratory reagents.
Disposal of all waste material should be in accordance with local guidelines.
Safety data sheet available for professional user on request.

Product safety labeling follows EU GHS guidance.

Contact phone: all countries: +49-621-7590

  • This kit contains components classified in accordance with the Regulation (EC) No. 1272/2008: 2‑methyl‑4‑isothiazolin‑3‑one hydrochloride (conc. ≥ 0.0015 %), thus the reagents may cause allergic skin reactions (H317).

  • The immunoparticles contain potentially infectious substances of animal origin and should be handled in accordance with Good Laboratory Practice (GLP) using appropriate precautions.

  • Avoid contact of reagents with the skin, eyes or mucous membranes. If contact does occur, immediately wash with generous amounts of water; otherwise, irritation can occur.

  • Immunoparticles R3 contains polystyrene nanoparticles.

  • Reagent Immunoparticles R3, once frozen, cannot be used anymore.

  • The assay is designed for fecal extract samples prepared using the specific CALEX® Cap.

  • Please equilibrate reagents, controls, calibrators and samples as described in this method sheet.

  • Ensure that samples have no bubbles prior to running the test.

  • Evaporation of calibrators and controls on the analyzer could lead to incorrect results. Run the assay immediately after loading the analyzer.

", "Language": "en" }, { "Name": "Caution", "Value": "", "Language": "en" }, { "Name": "QualityControl", "Value": "

Quality control

For quality control, use control materials as listed in the \"Order information\" section.

Validating instrument accuracy after calibration

Run the fCAL Control Set, Level I and Level II, in duplicate, after each new calibration, before running patient fecal sample extracts. Keep controls at room temperature for at least 30 min before starting analysis.

Validating daily runs

Run the fCAL Control Set, Level I and Level II, each day, before running patient fecal sample extracts to validate calibration curve stability. Single measurements of controls are sufficient.

The controls have assigned target values indicated on the control value sheet supplied with each lot of the fCAL Control Set. All control measurements must be within target values indicated on the control value sheet to obtain valid results for patient fecal sample extracts. If the control values are not valid, repeat quality control measurement with fresh controls. If control values remain invalid, recalibrate the instrument. If valid controls values cannot be reproduced after performing the steps described above, contact your local customer support.

Measuring patient samples

Once a calibration curve is established and validated with the quality controls, patient fecal extracts may be measured. Allow patient fecal sample extracts to equilibrate to room temperature for at least 30 minutes before starting analysis. Perform patient fecal extract measurement according to this instruction for use and instrument manual.

", "Language": "en" }, { "Name": "SpecimenPreparation", "Value": "

Specimen collection and preparation

The fCAL turbo is designed for calprotectin quantification in fecal sample extracts. Fecal samples are collected, extracted and diluted to a final concentration of 1:500 using the CALEX® Cap.

Specimen transport and storage

Stool specimens should be received for processing by the laboratory within 3 days of collection. Stool specimens may be shipped at room temperature or refrigerated. Stool specimens should be refrigerated at 2‑8 °C and extracted within 3 days of receipt at the laboratory. Do not store samples at elevated temperatures.

Stool sample extraction and extract stability in CALEX® Cap

Follow the instruction for use provided with the CALEX® Cap. Fecal sample extracts prepared using the CALEX® Cap will have a final dilution of 1:500 and are ready to use.

Liquid stool samples can be pipetted directly into the CALEX® Cap. Unscrew the blue cap and pipet 10 μL of stool sample into the device. Recap the CALEX® Cap and proceed with vortexing step according to the extraction procedure described and illustrated in the instruction for use delivered with the CALEX® Cap.

Important: Centrifuge the CALEX® Cap for 10 minutes at 1000‑3000 g prior to running the fCAL turbo procedure.

Fecal calprotectin in extracts obtained by the CALEX® Cap is stable at room temperature (23 °C) for 7 days, at 2‑8 °C for 15 days and at -20 °C for at least 23 months.

CALEX® Cap extracts can be frozen directly and stored within the CALEX® Cap. Extracts can be subject to four freeze‑thaw cycles. Prior to measurement, allow frozen extracts to equilibrate to room temperature, vortex thoroughly for 10 seconds and centrifuge according to the instruction for use of the assay.

", "Language": "en" } ] } }, { "ProductSpecVariant": { "MetaData": { "DocumentMaterialNumber": "0208910367190c503", "ProductName": "FCAL", "ProductLongName": "fCAL turbo", "Language": "en", "DocumentVersion": "2", "DocumentObjectID": "FF00000005B1D20E", "DocumentOriginID": "FF000000057E340E", "MaterialNumbers": [ "08910367190" ], "InstrumentReferences": [ { "ID": "9493", "BrandName": "cobas c 303" }, { "ID": "8481", "BrandName": "cobas c 503" } ], "DisclaimerText": "Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative." }, "Chapters": [ { "Name": "IntendedUse", "Value": "

Intended use

The fCAL turbo is an in vitro diagnostic assay intended for the quantitative measurement of fecal calprotectin, a neutrophilic protein that is a marker of intestinal mucosal inflammation, in human stool. fCAL turbo aids in the diagnosis of inflammatory bowel disease (IBD), specifically Crohn's disease (CD) and ulcerative colitis (UC) and aids in the differentiation of IBD from irritable bowel syndrome (IBS) in conjunction with other laboratory and clinical findings.

", "Language": "en" }, { "Name": "TestPrinciple", "Value": "

Test principle

The fCAL turbo test is a particle‑enhanced turbidimetric immunoassay (PETIA), which allows for automated quantification of calprotectin in fecal extracts on cobas c systems. Fecal samples are extracted with extraction buffer using the CALEX® Cap extraction device and applied at a final dilution of 1:500. The extracts are incubated with reaction buffer and mixed with polystyrene nanoparticles coated with calprotectin-specific antibodies (immunoparticles). Calprotectin available in the sample mediates immunoparticle agglutination. Sample turbidity, measured by light absorbance, increases with calprotectin-immunoparticle complex formation and is proportional to calprotectin concentration. The detected light absorbance allows quantification of calprotectin concentration via interpolation on an established calibration curve.

", "Language": "en" }, { "Name": "MeasuringRange", "Value": "

Limits and ranges

The measuring range for the fCAL turbo assay on thecobas c 303 analyzers and cobas c 503 analyzers is 30‑2000 µg/g. Samples > 2000 µg/g will be diluted automatically (1:10) by the analyzer, further extending the range to 30‑10000 µg/g.

", "Language": "en" }, { "Name": "ExpectedValues", "Value": "

Interpretation of results (clinical thresholds)

Calprotectin concentration

Interpretation

Follow-up

< 80 µg/g

normal

none

80‑160 µg/g

gray-zone/borderline

follow-up within 4‑6 weeks

> 160 µg/g

elevated

repeats as needed

Table 1: fCAL turbo diagnostic ranges

Calprotectin values < 80 μg/g
Fecal calprotectin values < 80 µg/g are not indicative of active inflammation in the gastrointestinal tract. Low fecal calprotectin levels can be used in conjunction with the patient’s clinical symptoms, medical history and other clinical and laboratory findings to determine the need for additional diagnostic work‑up. Specifically, for patients with a clinical and laboratory presentation suggesting a non‑inflammatory disorder such as IBS, fecal calprotectin values of < 80 µg/g can be used to support a decision to defer invasive testing.

Calprotectin values between and equal to 80 and 160 μg/g
Mid‑fecal calprotectin levels between and equal to 80 and 160 µg/g, also called gray‑zone levels, are not directly indicative of an active inflammation requiring immediate follow‑up with invasive testing. However, the presence of inflammation cannot be excluded. Re‑evaluation of fecal calprotectin levels after 4-6 weeks is recommended to determine the inflammatory status. This decision should be made by the clinician in conjunction with the patient’s clinical symptoms, medical history and other clinical and laboratory findings.

Calprotectin values > 160 μg/g
Fecal calprotectin values > 160 µg/g are indicative of neutrophil infiltrate in the gastrointestinal tract; therefore, this may signal the presence of active inflammatory disease. Elevated fecal calprotectin levels can be used in conjunction with the patient’s clinical symptoms, medical history and other clinical and laboratory findings to determine the need for further investigative procedures, including invasive procedures performed by specialists, to achieve an overall clinical diagnosis, in particular of IBD.

", "Language": "en" }, { "Name": "LimitationInterference", "Value": "

Limitations

• Test results should be interpreted in conjunction with information available from clinical assessment of the patient and other diagnostic procedures.
• False negative results could occur in patients who have granulocytopenia due to bone marrow depression.
• Some patients taking non‑steroidal anti‑inflammatory drugs (NSAID) will have elevations in their fecal calprotectin levels.
• Results may not be clinically applicable to children less than 4 years of age who have mildly increased fecal calprotectin levels.
• Patients with IBD fluctuate between active (inflammatory) and inactive stages of the disease. These stages must be considered when interpreting results of the fecal calprotectin assay.

Special wash programming required by the instrument manufacturer:
The manufacturer of the cobas c systems considers the use of special wash steps as mandatory when certain test combinations are run together on cobas c systems. All special wash programming necessary for avoiding carry-over is available via the cobas link. The latest version of the carry-over evasion list can be found with the NaOHD/SMS/SCCS Method Sheet provided by the instrument manufacturer. For further instructions, refer to the operator’s manual.

", "Language": "en" }, { "Name": "OrderInformation", "Value": "

OrderInformation (CC Reagents - cobas + Integra)

Order information

Analyzer(s) on which cobas c pack(s) can be used

08910367190

fCAL turbo (200 tests)

System‑ID 2149 001

cobas c 303, cobas c 503

Materials required (but not provided):

08910499190

fCAL Calibrator Set
fCAL Calibrator 1 (1 x 1 mL)
fCAL Calibrator 2 (1 x 1 mL)
fCAL Calibrator 3 (1 x 1 mL)
fCAL Calibrator 4 (1 x 1 mL)
fCAL Calibrator 5 (1 x 1 mL)
fCAL Calibrator 6 (1 x 1 mL)


Code 20719
Code 20720
Code 20721
Code 20722
Code 20723
Code 20724

08910502190

fCAL Control Set 
fCAL Control Level I  (3 x 1 mL)
fCAL Control Level II  (3 x 1 mL)


Code 20167
Code 20168

08910987001

CALEX® Cap (500 pcs)

", "Language": "en" }, { "Name": "SystemInformation", "Value": "

System information

FCAL: ACN 21490

", "Language": "en" }, { "Name": "Handling", "Value": "

Reagent handling

Ready for use

Loading of reagents

The reagents supplied are ready to use. Mix gently before loading onto the instrument. Avoid bubble formation.

", "Language": "en" }, { "Name": "TestDefinition", "Value": "

Application for fecal extracts

Test definition

Reaction time

10 min

Wavelength (sub/main)

800/546 nm

Reagent pipetting

Diluent
(H2O)

R1

100 µL

R3

16 µL

Sample volumes

Sample

Sample dilution

Sample

Diluent (H2O)

Normal

8 µL

-

-

Decreased

8 µL

8 µL

72 µL

Increased

8 µL

-

-

NOTE:
For technical reasons, it is necessary to specify a dummy unit (µg/mL) on cobas c analyzers. Values can be converted to the correct unit (µg/g) via the host computer.

", "Language": "en" }, { "Name": "StorageStability", "Value": "

Storage and stability

fCAL turbo

Shelf life at 2‑8 °C:

See expiration date on cobas c pack label.

On‑board in use and refrigerated on the analyzer:

store for up to 12 weeks at 5‑15 °C

Do not freeze reagents!

", "Language": "en" }, { "Name": "Calibration", "Value": "

Calibration

Calibrators

S1: fCAL Calibrator 1

S2: fCAL Calibrator 2

S3: fCAL Calibrator 3

S4: fCAL Calibrator 4

S5: fCAL Calibrator 5

S6: fCAL Calibrator 6

Apply the lot-specific fCAL Calibrator values for the 6-point calibration curve:

Calibration mode

Spline

Calibration frequency

Full calibration
• after reagent lot change
• after 9 weeks on‑board the analyzer
• after 9 weeks when using a single reagent lot
• as required following quality control procedures

To generate a reproducible calibration curve, equilibrate reagents R1 and R3 to the storage temperature of the analyzer by loading the cobas c pack at least 1 hour before calibration curve establishment. Keep calibrators as well as controls and patient samples at room temperature for at least 30 min before starting analysis. The calibration on cobas c 303 analyzers and cobas c 503 analyzers is performed in duplicate.

Traceability: This method has been standardized against internal reference material.

", "Language": "en" }, { "Name": "Limitations", "Value": "

Clinical evaluation

The clinical evaluation of fCAL turbo was assessed on the master system cobas c 501 analyzer. The results are also considered applicable to cobas c 303 analyzers and cobas c 503 analyzers.

The ability of the fCAL turbo to discriminate between patients with IBD and other non‑inflammatory gastrointestinal (GI) disorders, including IBS, was evaluated using clinical samples collected from 337 adult and pediatric patients. One hundred and thirty five patients had a final diagnosis of IBD (Crohn’s disease, ulcerative colitis or indeterminate colitis), 130 patients suffered from IBS and 72 patients presented with abdominal pain and/or diarrhea, or other GI‑related non‑inflammatory conditions. Final diagnosis was supported by endoscopic as well as other clinical findings.

Final
diagnosis

Distribution of patients results in numbers (%) within fCAL turbo diagnostic ranges

< 80 μg/g

80‑160 μg/g

> 160 μg/g

Total

IBD

12 (8.9 %)

15 (11.1 %)

108 (80 %)

135 (100 %)

IBS

99 (76.2 %)

15 (11.5 %)

16 (12.3 %)

130 (100 %)

Other GI

51 (70.8 %)

7 (9.7 %)

14 (19.4 %)

72 (100 %)

Table 2: Distributions of patients results within fCAL turbo diagnostic ranges

IBD vs. non‑IBD

Clinical decision point

80 μg/g

160 μg/g

Sensitivity (95 % CI)

91.1 % (85.0 %, 95.3 %)

80.0 % (72.3 %, 86.4 %)

Specificity (95 % CI)

74.3 % (67.7 %, 80.1 %)

85.1 % (79.5 %, 89.8 %)

PPV (95 % CI)

70.3 % (62.9 %, 76.9 %)

78.3 % (70.4 %, 84.8 %)

NPV (95 % CI)

92.6 % (87.4 %, 96.1 %)

86.4 % (80.9 %, 90.9 %)

ROC AUC (95 % CI)

0.916 (0.884, 0.947)

Table 3: Clinical performance characteristics of the fCAL turbo in discriminating IBD from non‑IBD − IBS and other GI‑related disorders, at 80 μg/g and 160 μg/g clinical decision points

IBD vs. IBS

Clinical decision point

80 μg/g

160 μg/g

Sensitivity (95 % CI)

91.1 % (85.0 %, 95.3 %)

80.0 % (72.3 %, 86.4 %)

Specificity (95 % CI)

76.2 % (67.9 %, 83.2 %)

87.7 % (80.8 %, 92.8 %)

PPV (95 % CI)

79.9 % (72.7 %, 85.9 %)

87.1 % (79.9 %, 92.4 %)

NPV (95 % CI)

89.2 % (81.9 %, 94.3 %)

80.9 % (73.4 %, 87.0 %)

ROC AUC (95 % CI)

0.929 (0.898, 0.960)

Table 4: Clinical performance characteristics of the fCAL turbo in discriminating IBD from IBS at 80 μg/g and 160 μg/g clinical decision points

CI − confidence interval
PPV − positive predictive value
NPV − negative predictive value
ROC AUC − area under receiver operating characteristic curve

Reference range

Stool samples were obtained from 141 apparently healthy normal adults (> 21 years of age) with no symptoms or signs of gastrointestinal disease. The test results were categorized by the assay cut‑offs.

Distribution of results within fCAL turbo diagnostic ranges

< 80 μg/g

80-160 μg/g

> 160 μg/g

Total

Number of subjects (%)

106 (75.2 %)

18 (12.8 %)

17 (12.1 %)

141 (100 %)

Table 5: Distribution of healthy subjects results within fCAL turbo diagnostic ranges

", "Language": "en" }, { "Name": "PerformanceData", "Value": "", "Language": "en" }, { "Name": "Precision", "Value": "

Specific performance data

The presented performance characteristics have been established on a cobas c 303 analyzer and cobas c 503 analyzer unless otherwise indicated, and should be considered as representative data. Results obtained in individual laboratories may differ.
For regulatory purposes, validation was performed using extracts obtained by manual weighing and extraction. The CALEX® Cap was validated for comparability with the manual extraction method on a cobas c 501 analyzer. Any changes to the directions for use, including special wash programming, may alter the stated performance characteristics of the assay and must be validated prior to implementation by the laboratory.

Method comparison

The method comparison study was performed according to the CLSI guideline EP09-A3. Forty‑five (45) clinical samples were measured on a cobas c 303 analyzer and cobas c 503 analyzer using 1 lot of fCAL turbo over 1 day in 1 calibration cycle. Reference values, with a final calprotectin concentration interval of 39.1‑9075.4 μg/g, were established with the fCAL turbo on a cobas c 501 analyzer. Bias was determined using Passing‑Bablok linear regression and Bland‑Altman analysis.

Bland‑Altman analysis

Passing-Bablok regression
analysis

Mean
bias

(95 % CI)

Lower
LoA

(95 % CI)

Upper
LoA

(95 % CI)


Slope

(95 % CI)


y‑Intercept

(95 % CI)

Bias at 80 μg/g

(95 % CI)

Bias at 160 μg/g

(95 % CI)


r

6.4 % (4.8 %, 7.9 %)

-3.7 % (-6.3 %, -1.0 %)

16.4 % (13.7 %, 19.0 %)

1.075 (1.049, 1.105)

-1.122 μg/g (-5.722 μg/g, 4.137 μg/g)

6.1 %
(1.5 %, 10.7 %)

6.8 %
(4.6 %, 8.7 %)

1.000

Table 6: Summary of Bland-Altman and Passing-Bablok regression analyses obtained on cobas c 303 analyzer vs. established reference values on cobas c 501 analyzer. (LoA = Limits of agreement)

Bland‑Altman analysis

Passing-Bablok regression
analysis

Mean
bias

(95 % CI)

Lower
LoA

(95 % CI)

Upper
LoA

(95 % CI)


Slope

(95 % CI)


y‑Intercept

(95 % CI)

Bias at 80 μg/g

(95 % CI)

Bias at 160 μg/g

(95 % CI)


r

-7.0 % (-9.1 %, -4.8 %)

-20.9 % (-24.6 %, -17.3 %)

7.0 % (3.3 %, 10.7 %)

0.9866 (0.9657, 1.005)

-7.28 μg/g (-12.18 μg/g, -5.32 μg/g)

-10.4 %
(-15.8 %, -9.2 %)

-5.9 %
(-8.5 %, 4.9 %)

0.998

Table 7: Summary of Bland-Altman and Passing-Bablok regression analyses obtained on cobas c 503 analyzer vs. established reference values on cobas c 501 analyzer. (LoA = Limits of agreement)

Within-laboratory precision

Repeatability and within‑laboratory precision were established according to the CLSI guideline EP05-A3. Six pooled stool specimen extracts with calprotectin concentrations covering the measuring range of the test and clinical decision points were tested over 5 days, in 2 runs per day, with 4 results generated per run. One reagent lot was used in the study.

ID

Mean [μg/g]

Within-run
(Repeatability)

Between-run

Between-day

Total
Precision

SD
[µg/g]

CV
[%]

SD
[µg/g]

CV
[%]

SD
[µg/g]

CV
[%]

SD
[µg/g]

CV
[%]

P1

59.3

1.8

3.0

1.8

0.9

0.6

1.0

1.92

3.2

P2

85.4

1.9

2.2

2.7

3.1

0.0

0.0

3.25

3.8

P3

184.1

1.8

1.0

0.9

0.5

2.8

1.5

3.44

1.9

P4

733.9

1.9

0.3

20.9

2.8

39.0

5.3

44.27

6.0

P5

1738.4

5.7

0.3

37.1

2.1

36.0

2.1

52.00

3.0

P6

6758.5

20.2

0.3

86.0

1.3

242.8

3.6

258.31

3.8

Table 8: Within-laboratory precision study results on the cobas c 303 analyzer

ID

Mean [μg/g]

Within-run
(Repeatability)

Between-run

Between-day

Total
Precision

SD
[µg/g]

CV
[%]

SD
[µg/g]

CV
[%]

SD
[µg/g]

CV
[%]

SD
[µg/g]

CV
[%]

P1

49.0

1.8

3.6

1.5

3.2

1.6

3.2

2.8

5.7

P2

64.5

1.8

2.7

1.6

2.4

4.3

6.7

4.9

7.6

P3

163.4

1.3

0.8

2.6

1.6

4.3

2.6

5.2

3.2

P4

735.2

1.8

0.2

10.6

1.4

27.4

3.7

29.4

4.0

P5

1743.0

6.6

0.4

29.2

1.7

75.1

4.3

80.8

4.6

P6

6657.9

27.2

0.4

105.3

1.6

0.0

0.0

108.7

1.6

Table 9: Within-laboratory precision study results on the cobas c 503 analyzer

Extraction reproducibility‑CALEX®Cap: 8.1‑19.7 % CV

The extraction reproducibility was established according to the CLSI guideline EP05‑A3 using a 2 days x 2 operators x 3 CALEX® Cap lots x 2 extractions x 3 replicates study design on the cobas c 501 analyzer. Twelve clinical stool specimens, including specimens with solid, semi‑solid and liquid consistency, with calprotectin concentrations in the range of 42.7‑3440.0 μg/g, were tested.

Sample carry-over

The sample carry-over was established according to the CLSI guideline EP10‑A2. No statistically significant sample carry-over with the fCAL turbo test on cobas c303 analyzers and cobas c 503 analyzers was detected.

Limit of Blank (LoB)

cobas c 303 analyzer: 9.8 μg/g

cobas c 503 analyzer: 2.6 μg/g

The LoB was established according to the CLSI guideline EP17-A2 with 4 negative (extraction buffer) samples. The samples were measured over 3 days in 5 replicates each day to produce 60 blank values. The LoB was calculated using non-parametric analysis. The study was performed with 1 reagent lot.

Limit of Detection (LoD)

cobas c 303 analyzer: 12.9 μg/g

cobas c 503 analyzer: 6.3 μg/g

The LoD was established according to the CLSI guideline EP17-A2 with 4 stool specimen extracts with concentrations corresponding to 1‑5 times the LoB value. The samples were measured over 3 days in 5 replicates each day to produce 60 values. The LoD was calculated using parametric analysis. The study was performed with 1 reagent lot.

Limit of Quantitation (LoQ)

cobas c 303 analyzer: 30 μg/g

cobas c 503 analyzer: 30 μg/g

The LoQ was established according to the CLSI guideline EP17-A2 with 4 low level stool specimen extracts. The samples were measured over 3 days in 5 replicates each day to produce a total of 15 replicates per sample. The study was performed with 1 reagent lot. The LoQ was defined as the lowest calprotectin concentration, which can be determined with a precision of < 20% CV using an acceptance criterion of LoQ ≤ 30 µg/g.

", "Language": "en" }, { "Name": "MethodComparison", "Value": "", "Language": "en" }, { "Name": "Summary", "Value": "

Summary

Gastroenterologists are often faced with the diagnostic difficulty of differentiating individuals with functional gastrointestinal disorders, such as irritable bowel syndrome (IBS), from those with inflammatory bowel disease (IBD). Many symptoms are common to both conditions, whereas other clinical features such as a predominance of diarrhea and rectal bleeding will increase the likelihood of inflammatory disease. The clinical differentiation between these conditions remains problematic and may result in delayed diagnosis. Furthermore, many individuals with IBS must undergo invasive procedures (endoscopy) to rule out an organic disorder. This has significant implications for health care costs as well as exposing individuals to the inherent risks associated with invasive procedures.

LREFOcchipinti K, Smith JW. Clin Colon Rectal Surg 2012;25(1):46-52
,
LREFPavlidis P, Chedgy FJ, Tibble JA Scand J Gastroenterol. 2013;48(9):1048-54.
,
LREFMindemark M, Larsson A. Clin Biochem. 2012;45(7-8):552-5
,
LREFWaugh N, Cummins E, Royle P et al. Health Technol Assess. 2013;17(55):xv-xix, 1-211
Diseases included in the IBD category include Crohn´s disease (CD), ulcerative colitis (UC) and indeterminate colitis. IBD represents chronic and often disabling lifelong inflammatory conditions – frequently diagnosed in young people in their late teens and early twenties. It is estimated that nearly 1.2 million Americans are living with IBD, and the prevalence is rising.
LREFKappelman MD, Moore KR, Allen JK et al. Dig Dis Sci. 2013;58(2):519-25
The main difference between CD and UC is the location and nature of the inflammatory condition. In UC, the disease is restricted to the colon, whereas in CD, inflammation may affect any part of the gastrointestinal tract – the ileocecal area being most often affected.
LREFStange EF, Travis SP, Vermeire S et al. J Crohns Colitis 2008;2(1):1-23
,
LREFVan Assche G, Dignass A, Panes J et al. J Crohns Colitis 2010;4(1):7-27
The most striking difference between IBS and IBD is that the former is non-inflammatory in nature. Therefore, one possibility is to measure surrogate markers of intestinal inflammation to differentiate between the two.
LREFTibble JA, Sigthorsson G, Foster R et al. Gastroenterol 2002;123(2):450-460.
,
LREFJahnsen J, Røseth AG, Aadland E. Tidsskr Nor Laegeforen 2008;128:743-5
Calprotectin is a calcium-binding protein found in neutrophilic granulocytes, monocytes, and macrophages, comprises up to 60 % of the total cytosolic protein content of neutrophils, resists metabolic degradation, and can be measured in feces.
LREFDale I, Brandtzaeg P, Fagerhol MK et al. Am J Clin Pathol 1985;84(1):24-34
,
LREFRøseth AG, Aadland E, Jahnsen J et al. Digestion 1997;58(2):176-180
,
LREFRøseth AG, Fagerhol MK, Aadland E et al. Scand J Gastroenterol 1992;27(9):793-798
Its use as a biomarker of intestinal inflammation has been extensively validated, showing consistently abnormal levels in the stool of individuals with IBD.
LREFFagerhol MK. Lancet 2000;356(9244):1783-4
,
LREFKonikoff MR, Denson LA. Inflamm Bowel Dis. 2006;12(6):524-34.
,
LREFVan Rheenen PF, Van de Vijver E, Fidler V. BMJ 2010;341:c3369. doi: 10.1136/bmj.c3369.
,
LREFBurri E, Beglinger C. Swiss Med Wkly 2012;142:w13557. doi: 10.4414/smw.2012.13557. eCollection 2012.

", "Language": "en" }, { "Name": "Reagents", "Value": "

Reagents - working solutions

Reagents

Quantity

Preparation

Reaction Buffer (R1)
MOPS buffered saline

25.4 mL

Ready to use

Immunoparticles (R3)
Polystyrene beads coated with avian antibodies against human calprotectin

6.5 mL

Ready to use

R1 is in position B and R3 is in position C. R3 refers to the reagent, which is pipetted at time point R3.

", "Language": "en" }, { "Name": "PrecautionsWarnings", "Value": "

Precautions and warnings

For in vitro diagnostic use.
Exercise the normal precautions required for handling all laboratory reagents.
Disposal of all waste material should be in accordance with local guidelines.
Safety data sheet available for professional user on request.

Product safety labeling follows GHS guidance.

Contact phone: 1-800-428-2336

• This kit contains 2-methyl-4-isothiazolin-3-one hydrochloride (conc. ≥ 0.0015 %), thus the reagents may cause allergic skin reactions (H317).
• The immunoparticles contain potentially infectious substances of animal origin and should be handled in accordance with good laboratory practice (GLP) using appropriate precautions.
• R1 contains MOPS (3-(N-morpholino)propanesulfonic acid) (< 1 %), that can be irritating to eyes and skin. Handle with due caution.
• Avoid contact of reagents with the skin, eyes or mucous membranes. If contact does occur, immediately wash with generous amounts of water; otherwise, irritation / burns can occur.
• Immunoparticles R3 contains polystyrene nanoparticles.
• Reagent immunoparticles R3, once frozen, cannot be used anymore. Freezing R3 will lead to reduced sensitivity and precision in low‑level samples and in the worst case to decreased measurement levels.
• The assay is designed for fecal extract samples prepared using the specific CALEX® Cap. Application of other extraction buffers could lead to incorrect results.
• Please equilibrate reagents, controls, calibrators and samples as described in this method sheet.
• Ensure that samples have no bubbles prior to running the test.
• Evaporation of calibrators and controls on the analyzer could lead to incorrect results. Run the assay immediately after loading the analyzer.

", "Language": "en" }, { "Name": "Caution", "Value": "", "Language": "en" }, { "Name": "QualityControl", "Value": "

Quality control

For quality control, use control materials as listed in the \"Order information\" section.

Validating instrument accuracy after calibration

Run the fCAL Control Set, Level I and Level II, in duplicate, after each new calibration, before running patient fecal sample extracts. Keep controls at room temperature for at least 30 min before starting analysis.

Validating daily runs

Run the fCAL Control Set, Level I and Level II, each day, before running patient fecal sample extracts to validate calibration curve stability. Single measurements of controls are sufficient.

The controls have assigned target values indicated on the control value sheet supplied with each lot of the fCAL Control Set. All control measurements must be within target values indicated on the control value sheet to obtain valid results for patient fecal sample extracts. If the control values are not valid, repeat quality control measurement with fresh controls. If control values remain invalid, recalibrate the instrument. If valid control values cannot be reproduced after performing the steps described above, contact Roche US Technical Support 1-800-428-2336.

Measuring patient samples

Once a calibration curve is established and validated with the quality controls, patient fecal extracts may be measured. Allow patient fecal sample extracts to equilibrate to room temperature for at least 30 minutes before starting analysis. Perform patient fecal extract measurement according to this instruction for use and instrument manual.

", "Language": "en" }, { "Name": "SpecimenPreparation", "Value": "

Specimen collection and preparation

The fCAL turbo is designed for calprotectin quantification in fecal sample extracts. Fecal samples are collected, extracted and diluted to a final concentration of 1:500 using the CALEX® Cap.

Specimen transport and storage

Stool specimens should be received for processing by the laboratory within 3 days of collection. Stool specimens may be shipped at room temperature or refrigerated. Stool specimens should be refrigerated at 2-8 °C and extracted within 3 days of receipt at the laboratory. Do not store samples at elevated temperatures.

Stool sample extraction and extract stability

Follow the instruction for use provided with the CALEX® Cap. Fecal sample extracts prepared using the CALEX® Cap will have a final dilution of 1:500 and are ready to use. Liquid stool samples can be pipetted directly into the CALEX® Cap. Unscrew the blue cap and pipet 10 μL of stool sample into the device. Recap the CALEX® Cap and proceed with vortexing step according to the extraction procedure described and illustrated in the instruction for use delivered with the CALEX® Cap.

Important: Centrifuge the CALEX® Cap for 10 minutes at 1000‑3000 g prior to running the fCAL turbo procedure.

CALEX® Cap extracts can be kept at room temperature for up to 2 hours, and after centrifugation, at 2-8 °C for up to 3.5 days (84 hours). For longer storage, freeze CALEX® Cap extracts at -20 °C. CALEX® Cap extracts can be subjected to 4 freeze-thaw cycles. Allow frozen extracts to equilibrate to room temperature for up to 2 hours before measurement. Prior to measurement, CALEX® Cap extract should be vortexed thoroughly for 10 seconds and centrifuged for 10 minutes at 1000‑3000 g.

Please note that extracts can be stored and frozen directly within the CALEX® Cap.

", "Language": "en" } ] } }, { "ProductSpecVariant": { "MetaData": { "DocumentMaterialNumber": "0008910332190c501", "ProductName": "FCAL", "ProductLongName": "fCAL turbo", "Language": "en", "DocumentVersion": "1", "DocumentObjectID": "FF00000003CED60E", "DocumentOriginID": "FF00000003CED50E", "MaterialNumbers": [ "08910332190" ], "InstrumentReferences": [ { "ID": "2324", "BrandName": "cobas c 502" }, { "ID": "309", "BrandName": "cobas c 501" } ], "DisclaimerText": "Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative." }, "Chapters": [ { "Name": "IntendedUse", "Value": "

Intended use

The fCAL turbo is an in vitro diagnostic assay intended for the quantitative measurement of fecal calprotectin, a neutrophilic protein that is a marker of intestinal mucosal inflammation, in human stool. fCAL turbo aids in the diagnosis of inflammatory bowel disease (IBD), specifically Crohn's disease (CD) and ulcerative colitis (UC) and aids in the differentiation of IBD from irritable bowel syndrome (IBS) in conjunction with other laboratory and clinical findings. The fCAL turbo is intended to be run on cobas c 501/502 systems.

", "Language": "en" }, { "Name": "TestPrinciple", "Value": "

Test principle

The fCAL turbo test is a particle‑enhanced turbidimetric immunoassay (PETIA), which allows for automated quantification of calprotectin in fecal extracts on cobas c systems. Fecal samples are extracted with extraction buffer using the CALEX® Cap extraction device and applied at a final dilution of 1:500. The extracts are incubated with reaction buffer and mixed with polystyrene nanoparticles coated with calprotectin-specific antibodies (immunoparticles). Calprotectin available in the sample mediates immunoparticle agglutination. Sample turbidity, measured by light absorbance, increases with calprotectin-immunoparticle complex formation and is proportional to calprotectin concentration. The detected light absorbance allows quantification of calprotectin concentration via interpolation on an established calibration curve.

", "Language": "en" }, { "Name": "MeasuringRange", "Value": "

Limits and ranges

The measuring range for the fCAL turbo assay on the cobas c 501/502 analyzers is 30‑2000 µg/g. Samples > 2000 µg/g will be diluted automatically (1:10) by the analyzer, further extending the range to 30‑10000 µg/g.

", "Language": "en" }, { "Name": "ExpectedValues", "Value": "

Interpretation of results (clinical thresholds)

Calprotectin concentration

Interpretation

Follow-up

< 80 µg/g

normal

none

80‑160 µg/g

gray-zone/borderline

follow-up within 4‑6 weeks

> 160 µg/g

elevated

repeats as needed

Table 1: fCAL turbo diagnostic ranges

Calprotectin values < 80 μg/g
Fecal calprotectin values < 80 µg/g are not indicative of active inflammation in the gastrointestinal tract. Low fecal calprotectin levels can be used in conjunction with the patient’s clinical symptoms, medical history and other clinical and laboratory findings to determine the need for additional diagnostic work‑up. Specifically, for patients with a clinical and laboratory presentation suggesting a non‑inflammatory disorder such as IBS, fecal calprotectin values of < 80 µg/g can be used to support a decision to defer invasive testing.

Calprotectin values between and equal to 80 and 160 μg/g
Mid‑fecal calprotectin levels between and equal to 80 and 160 µg/g, also called gray‑zone levels, are not directly indicative of an active inflammation requiring immediate follow‑up with invasive testing. However, the presence of inflammation cannot be excluded. Re‑evaluation of fecal calprotectin levels after 4-6 weeks is recommended to determine the inflammatory status. This decision should be made by the clinician in conjunction with the patient’s clinical symptoms, medical history and other clinical and laboratory findings.

Calprotectin values > 160 μg/g
Fecal calprotectin values > 160 µg/g are indicative of neutrophil infiltrate in the gastrointestinal tract; therefore, this may signal the presence of active inflammatory disease. Elevated fecal calprotectin levels can be used in conjunction with the patient’s clinical symptoms, medical history and other clinical and laboratory findings to determine the need for further investigative procedures, including invasive procedures performed by specialists, to achieve an overall clinical diagnosis, in particular of IBD.

", "Language": "en" }, { "Name": "LimitationInterference", "Value": "

Limitations

• Test results should be interpreted in conjunction with information available from clinical assessment of the patient and other diagnostic procedures.
• False negative results could occur in patients who have granulocytopenia due to bone marrow depression.
• Some patients taking non-steroidal anti-inflammatory drugs (NSAID) will have elevations in their fecal calprotectin levels.
• Results may not be clinically applicable to children less than 4 years of age who have mildly increased fecal calprotectin levels.
• Patients with IBD fluctuate between active (inflammatory) and inactive stages of the disease. These stages must be considered when interpreting results of the fecal calprotectin assay.

ACTION REQUIRED
Special Wash Programming: The use of special wash steps is mandatory when certain test combinations are run together on Roche/Hitachi cobas c systems. The latest version of the carry‑over evasion list can be found with the NaOHD-SMS-SmpCln1+2-SCCS Method Sheets. For further instructions refer to the operator’s manual. cobas c 502 analyzer: All special wash programming necessary for avoiding carry‑over is available via the cobas link, manual input is required in certain cases.

Where required, special wash/carry‑over evasion programming must be implemented prior to reporting results with this test.

", "Language": "en" }, { "Name": "OrderInformation", "Value": "

OrderInformation (CC Reagents - cobas + Integra)

Order information

Analyzer(s) on which cobas c pack(s) can be used

08910332 190

fCAL turbo (200 tests)

System‑ID 07 7626 2

cobas c 501/502

08910499 190

fCAL Calibrator Set
fCAL Calibrator 1 (1 x 1 mL)
fCAL Calibrator 2 (1 x 1 mL)
fCAL Calibrator 3 (1 x 1 mL)
fCAL Calibrator 4 (1 x 1 mL)
fCAL Calibrator 5 (1 x 1 mL)
fCAL Calibrator 6 (1 x 1 mL)

Code 719
Code 720
Code 721
Code 722
Code 723
Code 724

08910502 190

fCAL Control Set 
fCAL Control Level I  (3 x 1 mL)
fCAL Control Level II  (3 x 1 mL)


Code 167
Code 168

08910987 001

CALEX® Cap (500 pcs)

", "Language": "en" }, { "Name": "SystemInformation", "Value": "

System information

For cobas c 501 analyzer:

FCAL: ACN 462

For cobas c 502 analyzer:

FCAL: ACN 8462

", "Language": "en" }, { "Name": "Handling", "Value": "

Reagent handling

Ready for use

Loading of reagents

The reagents supplied are ready to use. Mix gently before loading onto the instrument. Avoid bubble formation.

", "Language": "en" }, { "Name": "TestDefinition", "Value": "

Application for fecal extracts

cobas c 501/502 test definition

Assay type

2 Point End

Reaction time / Assay points

10/36‑55

Wavelength (sub/main)

800/546 nm

Reaction direction

Increase

Units

µg/g

Reagent pipetting

Diluent (H2O)

R1

100 µL

R3

20 µL

Sample volumes

Sample

Sample dilution

Sample

Diluent (H2O)

Normal

10 µL

Decreased

10 µL

10 µL

90 µL

Increased

10 µL

Note

For technical reasons it is necessary to specify a dummy unit (µg/mL) on cobas c analyzers. Values can be converted to the correct unit (µg/g) via the host computer.

", "Language": "en" }, { "Name": "StorageStability", "Value": "

Storage and stability

fCAL turbo

Shelf life at 2‑8 °C:

See expiration date on cobas c pack label.

On‑board in use and refrigerated on the analyzer:

store for up to 3 months at 5‑12 °C

Do not freeze reagents!

", "Language": "en" }, { "Name": "Calibration", "Value": "

Calibration

Calibrators

S1: fCAL Calibrator 1

S2: fCAL Calibrator 2

S3: fCAL Calibrator 3

S4: fCAL Calibrator 4

S5: fCAL Calibrator 5

S6: fCAL Calibrator 6

Apply the lot-specific fCAL Calibrator values for the 6-point calibration curve:

Calibration mode

Spline

Calibration frequency

Full calibration
• after reagent lot change
• as required following quality control procedures

To generate a reproducible calibration curve equilibrate reagents R1 and R2 to the storage temperature of the analyzer by loading the cobas c pack at least 1 hour before calibration curve establishment. Keep calibrators as well as controls and patient samples at room temperature for at least 30 min before starting analysis. The calibration on cobas c 501/502 is performed in duplicates.

A calibration curve stability of 2 months, established for reagents stored on board, is defined in the instrument application.

Traceability: This method has been standardized against internal reference material.

", "Language": "en" }, { "Name": "Limitations", "Value": "

Clinical evaluation

The ability of the fCAL turbo to discriminate between patients with IBD and other non‑inflammatory gastrointestinal (GI) disorders, including IBS, was evaluated using clinical samples collected from 337 adult and pediatric patients. One hundred and thirty five patients had a final diagnosis of IBD (Crohn’s disease, ulcerative colitis or indeterminate colitis), 130 patients suffered from IBS and 72 patients presented with abdominal pain and/or diarrhea, or other GI‑related non‑inflammatory conditions. Final diagnosis was supported by endoscopic as well as other clinical findings.

Final diagnosis

Distribution of patients results in numbers (%) within fCAL turbo diagnostic ranges

< 80 μg/g

80‑160 μg/g

> 160 μg/g

Total

IBD

12 (8.9 %)

15 (11.1 %)

108 (80 %)

135 (100 %)

IBS

99 (76.2 %)

15 (11.5 %)

16 (12.3 %)

130 (100 %)

Other GI

51 (70.8 %)

7 (9.7 %)

14 (19.4 %)

72 (100 %)

Table 2: Distributions of patients results within fCAL turbo diagnostic ranges

IBD vs. non‑IBD

Clinical decision point

80 μg/g

160 μg/g

Sensitivity (95 % CI)

91.1 % (85.0 %, 95.3 %)

80.0 % (72.3 %, 86.4 %)

Specificity (95 % CI)

74.3 % (67.7 %, 80.1 %)

85.1 % (79.5 %, 89.8 %)

PPV (95 % CI)

70.3 % (62.9 %, 76.9 %)

78.3 % (70.4 %, 84.8 %)

NPV (95 % CI)

92.6 % (87.4 %, 96.1 %)

86.4 % (80.9 %, 90.9 %)

ROC AUC (95 % CI)

0.916 (0.884, 0.947)

Table 3: Clinical performance characteristics of the fCAL turbo in discriminating IBD from non‑IBD − IBS and other GI‑related disorders, at 80 μg/g and 160 μg/g clinical decision points

IBD vs. IBS

Clinical decision point

80 μg/g

160 μg/g

Sensitivity (95 % CI)

91.1 % (85.0 %, 95.3 %)

80.0 % (72.3 %, 86.4 %)

Specificity (95 % CI)

76.2 % (67.9 %, 83.2 %)

87.7 % (80.8 %, 92.8 %)

PPV (95 % CI)

79.9 % (72.7 %, 85.9 %)

87.1 % (79.9 %, 92.4 %)

NPV (95 % CI)

89.2 % (81.9 %, 94.3 %)

80.9 % (73.4 %, 87.0 %)

ROC AUC (95 % CI)

0.929 (0.898, 0.960)

Table 4: Clinical performance characteristics of the fCAL turbo in discriminating IBD from IBS at 80 μg/g and 160 μg/g clinical decision points

CI − confidence interval
PPV − positive predictive value
NPV − negative predictive value
ROC AUC − area under receiver operating characteristic curve

Reference range

Stool samples were obtained from 141 apparently healthy normal adults (> 21 years of age) with no symptoms or signs of gastrointestinal disease. The test results were categorized by the assay cut‑offs.

Distribution of results within fCAL turbo diagnostic ranges

< 80 μg/g

80-160 μg/g

> 160 μg/g

Total

Number of subjects (%)

106 (75.2 %)

18 (12.8 %)

17 (12.1 %)

141 (100 %)

Table 5: Distribution of healthy subjects results within fCAL turbo diagnostic ranges

", "Language": "en" }, { "Name": "PerformanceData", "Value": "", "Language": "en" }, { "Name": "Precision", "Value": "

Performance characteristics

The presented performance characteristics have been established on a cobas c 501 analyzer. For regulatory purposes validation was performed using extracts obtained by manual weighing and extraction. The CALEX® Cap was validated for comparability with the manual extraction method. Please refer to the CALEX® Cap IFU for results. Any changes to the directions for use, including special wash programming, may alter the stated performance characteristics of the assay and must be validated prior to implementation by the laboratory. Refer to clinical chemistry analyzer specific application notes for the performance characteristics on other clinical chemistry analyzers.

Please refer to the CALEX® Cap IFU for fCAL turbo performance with the CALEX®Cap device.

Method comparison

The method comparison study was performed according to the CLSI guideline EP09-A3. Two hundred and forty eight clinical samples were measured according to the instructions for use with the fCAL turbo and with BÜHLMANN fCAL® ELISA assay, with 220 samples yielding results within the measuring range for both tests. Measurements were performed over 18 days using 3 reagent lots.

Bland‑Altman analysis

Passing-Bablok regression analysis

Mean
bias

(95 % CI)

Lower
LoA

(95 % CI)

Upper
LoA

(95 % CI)


Slope

(95 % CI)


y‑Intercept

(95 % CI)

Bias at 80 μg/g

(95 % CI)

Bias at 160 μg/g

(95 % CI)


r

-0.5 % (-3.6 %, 2.7 %)

-46.5 % (-51.8 %, -41.1 %)

45.5 % (40.2 %, 50.9 %)

1.025 (0.990, 1.058)

-4.5 μg/g (-8.7, 0.3)

-3.1 %
(-7.2 %, 0.5 %)

-0.3 %
(-2.4 %, 2.7 %)

0.972

Table 6: Method comparison study results, (LoA= Limits of agreement)

Reproducibility (multisite precision evaluation study)

Reproducibility was established according to the CLSI guideline EP05-A3 by performing measurements at 3 laboratory sites. Eight pooled stool specimen extracts with calprotectin concentrations covering the measuring range of the test and clinical decision points were tested over 5 days, in 1 run per day, with 5 results generated per run. One reagent lot was used in the study.

ID

Mean [μg/g]

n

Within-run (repeatability)

Between-day

Between-site

Total precision

SD

%CV

SD

%CV

SD

%CV

SD

%CV

S01

47.2

75

3.6

7.6 %

2.4

5.0 %

0.0

0.0 %

4.3

9.1 %

S02

91.1

75

3.5

3.8 %

3.5

3.8 %

2.8

3.1 %

5.7

6.2 %

S03

185.4

75

5.1

2.7 %

2.7

1.4 %

5.5

3.0 %

7.9

4.3 %

S04

276.9

75

6.4

2.3 %

4.5

1.6 %

9.7

3.5 %

12.5

4.5 %

S05

674.5

75

12.9

1.9 %

1.2

0.2 %

22.8

3.4 %

26.3

3.9 %

S06

1519.6

75

25.3

1.7 %

17.8

1.2 %

62.3

4.1 %

69.6

4.6 %

S07

3343.8

75

54.6

1.6 %

35.6

1.1 %

100.0

3.0 %

119.4

3.6 %

S08

5475.6

75

72.1

1.3 %

35.8

0.7 %

154.2

2.8 %

173.9

3.2 %

Table 7: Reproducibility study results – within‑run, between‑day, between‑site and total precision estimates

Between‑lot precision

Between‑lot precision was established according to the CLSI guideline EP05-A3. Eight pooled stool extracts with calprotectin concentrations covering the measuring range of the test and clinical decision points were tested over 5 days, in 1 run per day, with 5 results generated per run. Three reagent lots were used in the study.

ID

Mean [μg/g]

n

Within-run (repeatability)

Between-day

Between-lot

Total precision

SD

%CV

SD

%CV

SD

%CV

SD

%CV

S01

45.2

75

3.22

7.1 %

1.36

3.0 %

3.70

8.2 %

5.09

11.3 %

S02

86.4

75

3.69

4.3 %

1.19

1.4 %

5.66

6.6 %

6.86

7.9 %

S03

175.8

75

5.04

2.9 %

0.29

0.2 %

9.90

5.6 %

11.11

6.3 %

S04

263.9

75

7.55

2.9 %

0.00

0.0 %

9.98

3.8 %

12.52

4.7 %

S05

647.4

75

15.47

2.4 %

0.00

0.0 %

15.28

2.4 %

21.74

3.4 %

S06

1460.7

75

33.66

2.3 %

11.64

0.8 %

41.01

2.8 %

54.32

3.7 %

S07

3234.5

75

71.23

2.2 %

8.90

0.3 %

130.29

4.0 %

148.76

4.6 %

S08

5303.1

75

97.42

1.8 %

11.18

0.2 %

163.87

3.1 %

190.97

3.6 %

Table 8: Between‑lot precision study results

Within-laboratory precision

Repeatability and within‑laboratory precision were established according to the CLSI guideline EP05-A3. Eight pooled stool specimen extracts with calprotectin concentrations covering the measuring range of the test and clinical decision points were tested over 20 days, in 2 runs per day, with 2 results generated per run. One reagent lot was used in the study.

ID

Mean [μg/g]

n

Repeatability

Between-run

Between-day

Within-laboratory

SD

%CV

SD

%CV

SD

%CV

SD

%CV

S01

42.9

80

3.6

8.3 %

1.2

2.7 %

1.1

2.5 %

3.9

9.1 %

S02

98.4

80

2.5

2.6 %

1.8

1.8 %

2.2

2.2 %

3.7

3.8 %

S03

166.5

80

4.3

2.6 %

0.8

0.5 %

1.9

1.2 %

4.8

2.9 %

S04

267.6

80

3.9

1.4 %

2.5

0.9 %

1.8

0.7 %

5.0

1.9 %

S05

642.0

80

20.1

3.1 %

14.9

2.3 %

0.0

0.0 %

25.1

3.9 %

S06

1414.2

80

19.6

1.4 %

11.1

0.8 %

3.5

0.2 %

22.8

1.6 %

S07

3251.4

80

40.8

1.3 %

21.4

0.7 %

19.7

0.6 %

50.1

1.5 %

S08

5405.6

80

40.2

0.7 %

56.6

1.0 %

34.5

0.6 %

77.5

1.4 %

Table 9: Within‑laboratory precision study results

", "Language": "en" }, { "Name": "MethodComparison", "Value": "", "Language": "en" }, { "Name": "Summary", "Value": "

Summary

Gastroenterologists are often faced with the diagnostic difficulty of differentiating individuals with functional gastrointestinal disorders, such as irritable bowel syndrome, from those with inflammatory bowel disease. Many symptoms are common to both conditions, whereas other clinical features such as a predominance of diarrhea and rectal bleeding will increase the likelihood of inflammatory disease. The clinical differentiation between these conditions remains problematic and may result in delayed diagnosis. Furthermore, many individuals with IBS must undergo invasive procedures (endoscopy) to rule out an organic disorder. This has significant implications for health care costs as well as exposing individuals to the inherent risks associated with invasive procedures.

LREFOcchipinti K, Smith JW. Clin Colon Rectal Surg 2012;25(1):46-52
,
LREFPavlidis P, Chedgy FJ, Tibble JA Scand J Gastroenterol. 2013;48(9):1048-54
,
LREFMindemark M, Larsson A. Clin Biochem. 2012;45(7-8):552-5
,
LREFWaugh N, Cummins E, Royle P et al. Health Technol Assess. 2013;17(55):xv-xix, 1-211
Diseases included in the IBD category include Crohn´s disease, ulcerative colitis and indeterminate colitis. IBD represents chronic and often disabling lifelong inflammatory conditions – frequently diagnosed in young people in their late teens and early twenties. It is estimated that nearly 1.2 million Americans are living with IBD, and the prevalence is rising.
LREFKappelman MD, Moore KR, Allen JK et al. Dig Dis Sci. 2013;58(2):519-25
The main difference between CD and UC is the location and nature of the inflammatory condition. In UC, the disease is restricted to the colon, whereas in CD, inflammation may affect any part of the gastrointestinal tract – the ileo-cecal area being most often affected.
LREFStange EF, Travis SP, Vermeire S et al. J Crohns Colitis 2008;2(1):1-23
,
LREFVan Assche G, Dignass A, Panes J et al. J Crohns Colitis 2010;4(1):7-27
The most striking difference between IBS and IBD is that the former is non-inflammatory in nature. Therefore, one possibility is to measure surrogate markers of intestinal inflammation to differentiate between the two.
LREFTibble JA, Sigthorsson G, Foster R et al. Gastroenterol 2002;123(2):450-460
,
LREFJahnsen J, Røseth AG, Aadland E. Tidsskr Nor Laegeforen 2008;128:743-5
Calprotectin is a calcium-binding protein found in neutrophilic granulocytes, monocytes, and macrophages, comprises up to 60 % of the total cytosolic protein content of neutrophils, resists metabolic degradation, and can be measured in feces.
LREFDale I, Brandtzaeg P, Fagerhol MK et al. Am J Clin Pathol 1985;84(1):24-34
,
LREFRøseth AG, Aadland E, Jahnsen J et al. Digestion 1997;58(2):176-180
,
LREFRøseth AG, Fagerhol MK, Aadland E et al. Scand J Gastroenterol 1992;27(9):793-798
Its use as a biomarker of intestinal inflammation has been extensively validated, showing consistently abnormal levels in the stool of individuals with IBD.
LREFFagerhol MK. Lancet 2000;356(9244):1783-4
,
LREFKonikoff MR, Denson LA. Inflamm Bowel Dis. 2006;12(6):524-34
,
LREFVan Rheenen PF, Van de Vijver E, Fidler V. BMJ 2010;341:c3369. doi: 10.1136/bmj.c3369.
,
LREFBurri E, Beglinger C. Swiss Med Wkly 2012;142:w13557. doi: 10.4414/smw.2012.13557. eCollection 2012.

", "Language": "en" }, { "Name": "Reagents", "Value": "

Reagents - working solutions

Reagents

Quantity

Preparation

Reaction Buffer (R1)
MOPS buffered saline

1 x
23.0 mL

Ready to use

Immunoparticles (R2)
Polystyrene beads coated with avian antibodies against human calprotectin

1 x
6.6 mL

Ready to use

R1 is in position B and R2 is in position C.

", "Language": "en" }, { "Name": "PrecautionsWarnings", "Value": "

Precautions and warnings

For in vitro diagnostic use.
Exercise the normal precautions required for handling all laboratory reagents.
Disposal of all waste material should be in accordance with local guidelines.
Safety data sheet available for professional user on request.

The immunoparticles contain potentially infectious substances of animal origin and should be handled in accordance with good laboratory practice (GLP) using appropriate precautions.
• R1 contains MOPS (3-(N-morpholino)propanesulfonic acid) (< 1 %), that can be irritating to eyes and skin. Handle with due caution.
• R2 contains polystyrene nanoparticles.
• R1 and R2 contain 2-Methyl-2H-isothiazol-3-one, a preservative agent, which is below the allowable limits (0.01 %).
• Do not mix reagents R1 and R2 of different reagent lots.
• Reagent R2, once frozen, cannot be used anymore. Freezing R2 will lead to reduced sensitivity and precision in low‑level samples and in the worst case to decreased measurement levels.
• The assay is designed for fecal extract samples prepared using the specific CALEX® Cap devices. Application of other extraction buffers could lead to incorrect results.
• Please equilibrate reagents, controls, calibrators and samples as described.
• Ensure that samples have no bubbles prior to running the test.
• Evaporation of calibrators and controls on the analyzer could lead to incorrect results. Run the assay immediately after loading the analyzer.

", "Language": "en" }, { "Name": "Caution", "Value": "", "Language": "en" }, { "Name": "QualityControl", "Value": "

Quality control

For quality control, use control materials as listed in the \"Order information\" section.

Validating instrument accuracy after calibration

Assay the fCAL Control Set, Level I and Level II, in duplicate, after each new calibration, before running patient fecal sample extracts. Keep controls at room temperature for at least 30 min before starting analysis.

Validating daily runs

Assay the fCAL Control Set, Level I and Level II, each day, before running patient fecal sample extracts to validate calibration curve stability. Single measurements of controls are sufficient.

The controls have assigned value ranges indicated on the QC datasheet supplied with each lot of the fCAL Control Set. All control measurements must be within the indicated value ranges to obtain valid results for patient fecal sample extracts. If the control values are not valid, repeat quality control measurement with fresh controls. If control values remain invalid, recalibrate the instrument. For U.S., contact BUHLMANN Diagnostics Corp, BDC at (844) 300-9799 (Mon-Fri 8:00AM - 5:00PM EST) if valid control values cannot be reproduced, after performing the steps described above. For rest of the world, contact BÜHLMANN Laboratories AG, at +41 61 487 12 12 (Mon-Fri 8:00AM - 5.00PM CET).

Measuring patient samples

Once a calibration curve is established and validated with the quality controls, patient fecals extracts may be measured. Allow patient fecal sample extracts to equilibrate to room temperature for at least 30 minutes before starting analysis. Perform patient fecal extract measurement according to this instruction for use and instrument manual.

", "Language": "en" }, { "Name": "SpecimenPreparation", "Value": "

Specimen collection and preparation

The fCAL turbo is designed for calprotectin quantification in fecal sample extracts. Fecal samples are collected, extracted and diluted to a final concentration of 1:500 using the CALEX® Cap device.

Specimen transport and storage

Stool specimens should be received for processing by the laboratory within 3 days of collection. Stool specimens may be shipped at room temperature or on cold packs. Stool specimens should be refrigerated at 2‑8 °C and extracted within 3 days of receipt at the laboratory.

Stability in CALEX® Cap extracts

For CALEX® Cap extract stability refer to the instruction for use provided with the CALEX® Cap (REF: 08910987 001).

Laboratories are responsible for validating use of alternate storage temperatures/timeframes.

Stool extraction using the CALEX® Cap:

Follow the instruction for use provided with the the CALEX® Cap kit. Fecal sample extracts prepared using the CALEX® Cap will have a final dilution of 1:500 and are ready to use.

Important: Centrifuge the CALEX® Cap device for 10 minutes at 1000‑3000 g prior to running the fCAL turbo procedure.

", "Language": "en" } ] } }, { "ProductSpecVariant": { "MetaData": { "DocumentMaterialNumber": "0108910332190c501", "ProductName": "FCAL", "ProductLongName": "fCAL turbo", "Language": "en", "DocumentVersion": "3", "DocumentObjectID": "FF000000058C890E", "DocumentOriginID": "FF000000040D4A0E", "MaterialNumbers": [ "08910332190" ], "InstrumentReferences": [ { "ID": "2324", "BrandName": "cobas c 502" }, { "ID": "309", "BrandName": "cobas c 501" } ], "DisclaimerText": "Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative." }, "Chapters": [ { "Name": "IntendedUse", "Value": "

Intended use

The fCAL turbo is an automated in vitro diagnostic test for the quantitative determination of calprotectin in human stool specimens intended as an aid in the assessment of intestinal mucosal inflammation.

LREFNilsen T et al.: J Clin Lab Anal 2017 ; 31(4). doi: 10.1002/jcla.22061
,
LREFMandic-Havelka A et al.: Clin Lab. 2017 ; 63(5):907-913.
,
LREFNoebauer B et al. : Biochem Med (Zagreb) 2017 ; 27(3):030710.
The assay results can be used as an aid to diagnosis in distinguishing organic, inflammatory disease of the gastrointestinal tract (inflammatory bowel disease, IBD, specifically Crohn’s disease (CD) or ulcerative colitis (UC)) from functional disease (irritable bowel syndrome, IBS),
LREFFagerhol MK: Lancet 2000; 356, 1783-4.
,
LREFTibble JA et al.: Gut 2000; 47, 506-13.
,
LREFTibble JA, Sigthorsson G, Foster R et al. Gastroenterol 2002;123(2):450-460.
,
LREFJahnsen J et al.: Tidsskr Nor Legeforen 2009; 129(8), 743-5.
,
LREFManz M. et al.: BMC Gastroenterology 2012; 12, 5.
,
LREFPavlidis P, Chedgy FJ, Tibble JA Scand J Gastroenterol. 2013;48(9):1048-54.
,
LREFKonikoff MR, Denson LA. Inflamm Bowel Dis. 2006;12(6):524-34.
in patients with chronic abdominal pain and as an aid to IBD disease monitoring.
LREFKonikoff MR, Denson LA. Inflamm Bowel Dis. 2006;12(6):524-34.
,
LREFLin et al.: Inflamm Bowel Dis 2014; 20: 1407-15.
,
LREFLobatón T et al.: J Crohns Colitis 2013, 641-51.
,
LREFLobatón T et al.: Inflamm Bowel Dis 2013; 19(5), 1034-42.
,
LREFWright et al.: Gastroenterology 2015; 148(5), 938-947.
,
LREFNaismith GD et al.: J Crohns Colitis 2014; 8, 1022-9.
,
LREFFerreiro-Iglesias R et al.: Scand J Gastroenterol 2015, 23, 1-6.
,
LREFFerreiro-Iglesias R1 et al. : J Clin Gastroenterol 2015; 50(2),147-51.
,
LREFGuardiola J. et al. Clinical Gastroenterology & Hepatology 2014; 12(11) 1865-70.
,
LREFLasson A et al.: United European Gastroenterol J 2015, 3(1) 72-9.
,
LREFBressler B et al.: Can J Gastroenterol Hepatol 2015, 29(7), 369-72.
,
LREFPeyrin-BL et al.: Am J Gastroenterol 2015, 110, 1324-38.
,
LREFRicciuto A et al.: Crit Rev Clin Lab Sci. 2019; 56(5):307-320.
For laboratory use only.

", "Language": "en" }, { "Name": "TestPrinciple", "Value": "

Test principle

The fCAL turbo test is a particle‑enhanced turbidimetric immunoassay (PETIA), which allows for automated quantification of calprotectin in fecal extracts on cobas c systems. Fecal samples are extracted with extraction buffer using the CALEX® Cap extraction device and applied at a final dilution of 1:500. The extracts are incubated with reaction buffer and mixed with polystyrene nanoparticles coated with calprotectin-specific antibodies (immunoparticles). Calprotectin available in the sample mediates immunoparticle agglutination. Sample turbidity, measured by light absorbance, increases with calprotectin-immunoparticle complex formation and is proportional to calprotectin concentration. The detected light absorbance allows quantification of calprotectin concentration via interpolation on an established calibration curve.

", "Language": "en" }, { "Name": "MeasuringRange", "Value": "

Limits and ranges

The measuring range for the fCAL turbo assay on the cobas c 501/502 analyzers is 30‑2000 µg/g. Samples > 2000 µg/g will be diluted automatically (1:10) by the analyzer, further extending the range to 30‑10000 µg/g.

", "Language": "en" }, { "Name": "ExpectedValues", "Value": "

Interpretation of results

Distinguishing organic disease from functional gastrointestinal disease

Determination of fecal calprotectin levels can be used as a reliable and simple aid in distinguishing organic from functional gastrointestinal diseases.

LREFFagerhol MK: Lancet 2000; 356, 1783-4.
,
LREFTibble JA et al.: Gut 2000; 47, 506-13.
,
LREFTibble JA, Sigthorsson G, Foster R et al. Gastroenterol 2002;123(2):450-460.
,
LREFJahnsen J et al.: Tidsskr Nor Legeforen 2009; 129(8), 743-5.
,
LREFManz M. et al.: BMC Gastroenterology 2012; 12, 5.
,
LREFPavlidis P, Chedgy FJ, Tibble JA Scand J Gastroenterol. 2013;48(9):1048-54.
,
LREFKonikoff MR, Denson LA. Inflamm Bowel Dis. 2006;12(6):524-34.
BÜHLMANN recommends applying the following cut‑off values:

Clinical thresholds

Calprotectin concentration

Interpretation

Follow-up

< 80 µg/g

normal

none

80‑160 µg/g

gray-zone/borderline

follow-up within 4‑6 weeks

> 160 µg/g

elevated

repeats as needed

Table 1: fCAL turbo diagnostic ranges.

The result categories are based on data from clinical studies performed by BÜHLMANN and are BÜHLMANN’s recommendations. All test results should be interpreted in conjunction with information available from the patient’s clinical symptoms, medical history, and other clinical and laboratory findings:

Calprotectin values < 80 μg/g
Fecal calprotectin values < 80 µg/g are not indicative of active inflammation in the gastrointestinal tract. Patients with low calprotectin levels are not likely to be in need of invasive procedures to determine the inflammation cause.

LREFFagerhol MK: Lancet 2000; 356, 1783-4.

Calprotectin values between and equal to 80 and 160 μg/g
Mid‑fecal calprotectin levels between and equal to 80 and 160 µg/g, also called gray‑zone levels, are not directly indicative of an active inflammation requiring immediate follow‑up with invasive testing. However, the presence of inflammation cannot be excluded. Re‑evaluation of fecal calprotectin levels after 4-6 weeks is recommended to determine the inflammatory status.

Calprotectin values > 160 μg/g
Fecal calprotectin values > 160 µg/g are indicative of neutrophil infiltrate in the gastrointestinal tract; therefore, this may signal the presence of active inflammatory disease. Appropriate further investigative procedures by specialists are suggested to achieve an overall clinical diagnosis.

", "Language": "en" }, { "Name": "LimitationInterference", "Value": "

Limitations

• Test results should be interpreted in conjunction with information available from clinical assessment of the patient and other diagnostic procedures.
• For IBD disease monitoring, multiple fecal calprotectin measurements performed at up to 4 weeks intervals have been suggested to have best diagnostic accuracy in predicting clinical relapse in patients.

LREFMolander P et al.: Journal of Crohn's and Colitis 2015, 33-40.
,
LREFDe Vos M et al.: Inflamm Bowel Dis. 2013; 19, 2111-2117.

• Intake of non‑steroidal anti‑inflammatory drugs (NSAID) may lead to elevated fecal calprotectin levels.
• Results may not be clinically applicable to children less than 4 years of age who have mildly increased fecal calprotectin levels.
LREFFagerberg UL et al.: J Pediatr Gastroenterol Nutr 2005; 40, 450-5.
,
LREFLi F. et al.: PLoS ONE 10(3) (2015).
,
LREFZhu Q. et al. PLoS ONE 11 (3) (2016).
,
LREFPeura S. et al.: Scand J Clin Lab Invest 2018; 78(1-2): 120-124.

Special wash programming required by the instrument manufacturer:
The manufacturer of the cobas c systems considers the use of special wash steps as mandatory when certain test combinations are run together on cobas c systems. The latest version of the carry‑over evasion list can be found with the NaOHD-SMS-SmpCln1+2-SCCS Method Sheets provided by the instrument manufacturer. For further instructions refer to the operator’s manual. cobas c 502 analyzer: All special wash programming necessary for avoiding carry-over is available via the cobas link, manual input is required in certain cases.

Where required, special wash/carry‑over evasion programming must be implemented prior to reporting results with this test.

", "Language": "en" }, { "Name": "OrderInformation", "Value": "

OrderInformation (CC Reagents - cobas + Integra)

Order information

Analyzer(s) on which cobas c pack(s) can be used

08910332190

fCAL turbo (200 tests)

System‑ID 07 7626 2

cobas c 501/502

Materials required (but not provided):

08910499190

fCAL Calibrator Set
fCAL Calibrator 1 (1 x 1 mL)
fCAL Calibrator 2 (1 x 1 mL)
fCAL Calibrator 3 (1 x 1 mL)
fCAL Calibrator 4 (1 x 1 mL)
fCAL Calibrator 5 (1 x 1 mL)
fCAL Calibrator 6 (1 x 1 mL)

Code 719
Code 720
Code 721
Code 722
Code 723
Code 724

08910502190

fCAL Control Set 
fCAL Control Level I  (3 x 1 mL)
fCAL Control Level II  (3 x 1 mL)

08910987001

CALEX® Cap (500 pcs)

", "Language": "en" }, { "Name": "SystemInformation", "Value": "

System information

For cobas c 501 analyzer:

FCAL: ACN 462

For cobas c 502 analyzer:

FCAL: ACN 8462

", "Language": "en" }, { "Name": "Handling", "Value": "

Reagent handling

Ready for use

Loading of reagents

The reagents supplied are ready to use. Mix gently before loading onto the instrument. Avoid bubble formation.

", "Language": "en" }, { "Name": "TestDefinition", "Value": "

Application for fecal extracts

cobas c 501/502 test definition

Assay type

2 Point End

Reaction time / Assay points

10/36‑55

Wavelength (sub/main)

800/546 nm

Reaction direction

Increase

Units

µg/g

Reagent pipetting

Diluent (H2O)

R1

100 µL

R3

20 µL

Sample volumes

Sample

Sample dilution

Sample

Diluent (H2O)

Normal

10 µL

Decreased

10 µL

10 µL

90 µL

Increased

10 µL

", "Language": "en" }, { "Name": "StorageStability", "Value": "

Storage and stability

fCAL turbo

Shelf life at 2‑8 °C:

See expiration date on cobas c pack label.

On‑board in use and refrigerated on the analyzer:

store for up to 12 weeks at 5‑12 °C

Do not freeze reagents!

", "Language": "en" }, { "Name": "Calibration", "Value": "

Calibration

Calibrators

S1: fCAL Calibrator 1

S2: fCAL Calibrator 2

S3: fCAL Calibrator 3

S4: fCAL Calibrator 4

S5: fCAL Calibrator 5

S6: fCAL Calibrator 6

Manually configure calibrators using the codes listed in the \"Order information\" section.

Apply the lot-specific fCAL Calibrator values for the 6-point calibration curve:

Calibration mode

Spline

Calibration frequency

Full calibration
• after reagent lot change
• after 8 weeks on‑board the analyzer
• after 8 weeks when using a single reagent lot
• as required following quality control procedures

To generate a reproducible calibration curve, equilibrate reagents R1 and R3 to the storage temperature of the analyzer by loading the cobas c pack at least 1 hour before calibration curve establishment. Keep calibrators at room temperature for at least 30 min before starting analysis. The calibration on cobas c 501/502 analyzers is performed in duplicate.

", "Language": "en" }, { "Name": "Limitations", "Value": "

Clinical evaluation

The ability of the fCAL turbo to discriminate between patients with IBD and other non-inflammatory GI disorders, including IBS, was evaluated using clinical samples collected from 295 patients and extracted using the CALEX® Cap. One hundred and twenty seven (127) patients had a final diagnosis of IBD (Crohn’s disease, ulcerative colitis or indeterminate colitis), 103 patients suffered from IBS and 65 patients presented with abdominal pain and/or diarrhea, or other GI-related non-inflammatory conditions. Final diagnosis was supported by endoscopic as well as other clinical findings.

The optimal cut‑off combination for these patient pools could be defined by ROC analysis at 80 µg/g and 160 µg/g calprotectin (table 3 and 5), which is slightly more stringent than a combination of a more sensitive lower cut‑off of 50 µg/g with lower performance in specificity, and an upper cut‑off 200 µg/g with slightly lower sensitivity (table 4 and 6).

Final
diagnosis

Distribution of patients results in numbers (%) within fCAL turbo diagnostic ranges

< 80 μg/g

80‑160 μg/g

> 160 μg/g

Total

IBD

11 (8.7 %)

8 (6.3 %)

108 (85 %)

127 (100 %)

IBS

75 (72.8 %)

11 (10.7 %)

17 (16.5 %)

103 (100 %)

Other GI

42 (64.6 %)

8 (12.3 %)

15 (23.1 %)

65 (100 %)

Table 2: Distribution of patients results within fCAL turbo diagnostic ranges

IBD vs. non‑IBD

Clinical decision point

80 μg/g

160 μg/g

Sensitivity (95 % CI)

91.3 % (85.0 %, 95.6 %)

85.0 % (77.6 %, 90.7 %)

Specificity (95 % CI)

69.6 % (62.1 %, 76.5 %)

81.0 % (74.2 %, 86.6 %)

PPV (95 % CI)

69.5 % (61.9 %, 76.3 %)

77.1 % (69.3 %, 83.8 %)

NPV (95 % CI)

91.4 % (85.1 %, 95.6 %)

87.7 % (81.5 %, 92.5 %)

ROC AUC (95 % CI)

0.912 (0.878, 0.946)

Table 3: Clinical performance characteristics of the fCAL turbo in discriminating IBD from non‑IBD − IBS and other GI‑related disorders, at 80 μg/g and 160 μg/g clinical decision points

IBD vs. non‑IBD

Clinical decision point

50 μg/g

200 μg/g

Sensitivity (95 % CI)

94.5 % (89.0 %, 97.8 %)

80.3 % (72.3 %, 86.8 %)

Specificity (95 % CI)

62.5 % (54.7 %, 69.8 %)

85.7 % (79.5 %, 90.6 %)

PPV (95 % CI)

65.6 % (58.2 %, 72.4 %)

81.0 % (73.0 %, 87.4 %)

NPV (95 % CI)

93.8 % (87.5 %, 97.5 %)

85.2 % (78.9 %, 90.2 %)

Table 4: Clinical performance characteristics of the fCAL turbo in discriminating IBD from non‑IBD – IBS and other GI‑related disorders, at 50 µg/g and 200 µg/g clinical decision points

IBD vs. IBS

Clinical decision point

80 μg/g

160 μg/g

Sensitivity (95 % CI)

91.3 % (85.0 %, 95.6 %)

85.0 % (77.6 %, 90.7 %)

Specificity (95 % CI)

72.8 % (63.2 %, 81.1 %)

83.5 % (74.9 %, 90.1 %)

PPV (95 % CI)

80.6 % (73.1 %, 86.7 %)

86.4 % (79.1 %, 91.9 %)

NPV (95 % CI)

87.2 % (78.3 %, 93.4 %)

81.9 % (73.2 %, 88.7 %)

ROC AUC (95 % CI)

0.925 (0.892, 0.958)

Table 5: Clinical performance characteristics of the fCAL turbo in discriminating IBD from IBS at 80 μg/g and 160 μg/g clinical decision points

IBD vs. IBS

Clinical decision point

50 μg/g

200 μg/g

Sensitivity (95 % CI)

94.5 % (89.0 %, 97.8 %)

80.3 % (72.3 %, 86.8 %)

Specificity (95 % CI)

67.0 % (57.0 %, 75.9 %)

88.3 % (80.5 %, 93.8 %)

PPV (95 % CI)

77.9 % (70.5 %, 84.2 %)

89.5 % (82.3 %, 94.4 %)

NPV (95 % CI)

90.8 % (81.9 %, 96.2 %)

78.4 % (69.9 %, 85.5 %)

Table 6: Clinical performance characteristics of the fCAL turbo in discriminating IBD from IBS at 50 µg/g and 200 µg/g clinical decision points

CI − confidence interval
PPV − positive predictive value
NPV − negative predictive value
ROC AUC − area under receiver operating characteristic curve

", "Language": "en" }, { "Name": "PerformanceData", "Value": "", "Language": "en" }, { "Name": "Precision", "Value": "

Specific performance data

The presented performance characteristics should be considered as representative data. Results obtained in individual laboratories may differ. For regulatory purposes validation was performed using extracts obtained by manual weighing and extraction. The CALEX® Cap was validated for comparability with the manual extraction method. Any changes to the directions for use, including special wash programming, may alter the stated performance characteristics of the assay and must be validated prior to implementation by the laboratory.

Method comparison

fCALturbo CALEX®Cap vs BÜHLMANN fCAL®ELISA CALEX®Cap

The method comparison study was performed according to the CLSI guideline EP09-A3. One hundred and ninety nine (199) clinical samples were measured using one lot of fCAL turbo over 18 days in one calibration cycle. Reference values, with a final calprotectin concentration interval of 30.3‑1672.5 µg/g, were established with the BÜHLMANN fCAL® ELISA. Samples were extracted using the CALEX® Cap. Single determinations from CALEX® Cap extracts were performed in both methods. Bias was determined using Passing‑Bablok linear regression and Bland‑Altman analysis.

Bland‑Altman analysis

Passing-Bablok regression
analysis

Mean
bias

(95 % CI)

Lower
LoA

(95 % CI)

Upper
LoA

(95 % CI)

Slope

(95 % CI)

Intercept

(95 % CI)

Bias at 80 μg/g

(95 % CI)

Bias at 160 μg/g

(95 % CI)

r

0.68 % (-2.6 %, 4.0 %)

-46.0 % (-51.6 %, -40.3 %)

47.3 % (41.6 %, 53.0 %)

1.139 (1.104, 1.172)

-18.3 μg/g (-24.4 μg/g, -13.2 μg/g)

-9.0 %
(-15.1 %, -3.1 %)

2.4 %
(-1.2 %, 5.4 %)


0.982

Table 9: Method comparison study results, (LoA= Limits of agreement)

fCALturbo CALEX®Cap vs BÜHLMANN fCAL®ELISA manual extraction

The method comparison study was performed according to the CLSI guideline EP09‑A3. One hundred and sixty eight (168) clinical samples were extracted using three lots of the CALEX® Cap and measured using one lot of fCAL turbo over 18 days in one calibration cycle. Reference values, with a final calprotectin concentration interval of 30.5‑1573.8 µg/g, were established using the manual extraction method and extract measurement with the BÜHLMANN fCAL® ELISA. Extracts were measured in single determinations in both methods. Bias was determined using Passing‑Bablok linear regression and Bland‑Altman analysis.

Bland‑Altman analysis

Passing-Bablok regression
analysis

Mean
bias

(95 % CI)

Lower
LoA

(95 % CI)

Upper
LoA

(95 % CI)

Slope

(95 % CI)

Intercept

(95 % CI)

Bias at 80 μg/g

(95 % CI)

Bias at 160 μg/g

(95 % CI)

r

11.1 % (5.5 %, 16.6 %)

-60.7 % (-70.3 %, -51.2 %)

82.8 % (73.3 %, 92.4 %)

1.336 (1.265, 1.429)

-31.7 μg/g (-44.1 μg/g, -19.4 μg/g)

-6.0 %
(-16.4 %, 7.1 %)

13.8 %
(8.1 %, 23.2 %)


0.955

Table 10: Method comparison study result, (LoA= Limits of agreement)

Reproducibility (multisite precision evaluation study): 3.2‑9.1 % CV

Reproducibility was established according to the CLSI guideline EP05-A3 using a 3 laboratory sites x 5 days x 5 replicates study design. Eight pooled stool specimen extracts with calprotectin concentrations ranging from 47.2‑5475.6 µg/g were tested.

Between‑lot precision: 2.4‑8.2 % CV

Between‑lot precision was established according to the CLSI guideline EP05‑A3 using a 3 lots x 5 days x 5  replicates study design. Eight pooled stool specimen extracts with calprotectin concentrations ranging from 45.2‑5303.1 µg/g were tested.

Repeatability: 0.7‑8.3 % CV
Within-laboratory precision: 1.4‑9.1 % CV

Repeatability and within‑laboratory precision were established according to the CLSI guideline EP05‑A3 using the standardized 20 days x 2 runs x 2 replicates study design. Eight pooled stool specimen extracts with calprotectin concentrations ranging from 42.9‑5405.6 µg/g were tested.

Extraction reproducibilityCALEX®Cap: 8.1‑19.7 % CV

The extraction reproducibility was established according to the CLSI guideline EP05‑A3 using a 2 days x 2 operators x 3 CALEX® Cap lots x 2 extractions x 3 replicates study design. Twelve clinical stool specimens, including specimens with solid, semi‑solid and liquid consistency, with calprotectin concentrations in the range of 42.7‑3440.0 μg/g, were tested.

", "Language": "en" }, { "Name": "MethodComparison", "Value": "", "Language": "en" }, { "Name": "Summary", "Value": "", "Language": "en" }, { "Name": "Reagents", "Value": "

Reagents - working solutions

Reagents

Quantity

Preparation

Reaction Buffer (R1)
MOPS buffered saline

23.0 mL

Ready to use

Immunoparticles (R3)
Polystyrene beads coated with avian antibodies against human calprotectin

6.6 mL

Ready to use

R1 is in position B and R3 is in position C. R3 refers to the reagent, which is pipetted at time point R3.

", "Language": "en" }, { "Name": "PrecautionsWarnings", "Value": "

Precautions and warnings

For in vitro diagnostic use.
Exercise the normal precautions required for handling all laboratory reagents.
Disposal of all waste material should be in accordance with local guidelines.
Safety data sheet available for professional user on request.

Product safety labeling follows EU GHS guidance.

Contact phone: all countries: +49-621-7590

  • This kit contains components classified in accordance with the Regulation (EC) No. 1272/2008: 2‑methyl‑4‑isothiazolin‑3‑one hydrochloride (conc. ≥ 0.0015 %), thus the reagents may cause allergic skin reactions (H317).

  • The immunoparticles contain potentially infectious substances of animal origin and should be handled in accordance with Good Laboratory Practice (GLP) using appropriate precautions.

  • Avoid contact of reagents with the skin, eyes or mucous membranes. If contact does occur, immediately wash with generous amounts of water; otherwise, irritation / burns can occur.

  • Immunoparticles R3 contains polystyrene nanoparticles.

  • Reagent Immunoparticles R3, once frozen, cannot be used anymore.

  • The assay is designed for fecal extract samples prepared using the specific CALEX® Cap.

  • Please equilibrate reagents, controls, calibrators and samples as described in this method sheet.

  • Ensure that samples have no bubbles prior to running the test.

  • Evaporation of calibrators and controls on the analyzer could lead to incorrect results. Run the assay immediately after loading the analyzer.

", "Language": "en" }, { "Name": "Caution", "Value": "", "Language": "en" }, { "Name": "QualityControl", "Value": "

Quality control

For quality control, use control materials as listed in the \"Order information\" section.

Manually configure QC material using non-Roche QC material codes.

Validating instrument accuracy after calibration

Run the fCAL Control Set, Level I and Level II, in duplicate, after each new calibration, before running patient fecal sample extracts. Keep controls at room temperature for at least 30 min before starting analysis.

Validating daily runs

Run the fCAL Control Set, Level I and Level II, each day, before running patient fecal sample extracts to validate calibration curve stability. Single measurements of controls are sufficient.

The controls have assigned target values indicated on the control value sheet supplied with each lot of the fCAL Control Set. All control measurements must be within target values indicated on the control value sheet to obtain valid results for patient fecal sample extracts. If the control values are not valid, repeat quality control measurement with fresh controls. If control values remain invalid, recalibrate the instrument. If valid controls values cannot be reproduced after performing the steps described above, contact your local customer support.

Measuring patient samples

Once a calibration curve is established and validated with the quality controls, patient fecal extracts may be measured. Allow patient fecal sample extracts to equilibrate to room temperature for at least 30 minutes before starting analysis. Perform patient fecal extract measurement according to this instruction for use and instrument manual.

", "Language": "en" }, { "Name": "SpecimenPreparation", "Value": "

Specimen collection and preparation

The fCAL turbo is designed for calprotectin quantification in fecal sample extracts. Fecal samples are collected, extracted and diluted to a final concentration of 1:500 using the CALEX® Cap.

Specimen transport and storage

Stool specimens should be received for processing by the laboratory within 3 days of collection. Stool specimens may be shipped at room temperature or refrigerated. Stool specimens should be refrigerated at 2‑8 °C and extracted within 3 days of receipt at the laboratory. Do not store samples at elevated temperatures.

Stool sample extraction and extract stability in CALEX® Cap

Follow the instruction for use provided with the CALEX® Cap. Fecal sample extracts prepared using the CALEX® Cap will have a final dilution of 1:500 and are ready to use.

Liquid stool samples can be pipetted directly into the CALEX® Cap. Unscrew the blue cap and pipet 10 μL of stool sample into the device. Recap the CALEX® Cap and proceed with vortexing step according to the extraction procedure described and illustrated in the instruction for use delivered with the CALEX® Cap.

Important: Centrifuge the CALEX® Cap for 10 minutes at 1000‑3000 g prior to running the fCAL turbo procedure.

Fecal calprotectin in extracts obtained by the CALEX® Cap is stable at room temperature (23 °C) for 7 days, at 2‑8 °C for 15 days and at -20 °C for at least 23 months. CALEX® Cap extracts can be frozen directly and stored within the CALEX® Cap. Extracts can be subject to four freeze‑thaw cycles. Prior to measurement, allow frozen extracts to equilibrate to room temperature, vortex thoroughly for 10 seconds and centrifuge according to the instruction for use of the assay.

", "Language": "en" } ] } }, { "ProductSpecVariant": { "MetaData": { "DocumentMaterialNumber": "0208910332190c501", "ProductName": "FCAL", "ProductLongName": "fCAL turbo", "Language": "en", "DocumentVersion": "3", "DocumentObjectID": "FF00000005A3E00E", "DocumentOriginID": "FF00000005A3E00E", "MaterialNumbers": [ "08910332190" ], "InstrumentReferences": [ { "ID": "2324", "BrandName": "cobas c 502" }, { "ID": "309", "BrandName": "cobas c 501" } ], "DisclaimerText": "Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative." }, "Chapters": [ { "Name": "IntendedUse", "Value": "

Intended use

The fCAL turbo is an in vitro diagnostic assay intended for the quantitative measurement of fecal calprotectin, a neutrophilic protein that is a marker of intestinal mucosal inflammation, in human stool. fCAL turbo aids in the diagnosis of inflammatory bowel disease (IBD), specifically Crohn's disease (CD) and ulcerative colitis (UC) and aids in the differentiation of IBD from irritable bowel syndrome (IBS) in conjunction with other laboratory and clinical findings.

", "Language": "en" }, { "Name": "TestPrinciple", "Value": "

Test principle

The fCAL turbo test is a particle‑enhanced turbidimetric immunoassay (PETIA), which allows for automated quantification of calprotectin in fecal extracts on cobas c systems. Fecal samples are extracted with extraction buffer using the CALEX® Cap extraction device and applied at a final dilution of 1:500. The extracts are incubated with reaction buffer and mixed with polystyrene nanoparticles coated with calprotectin-specific antibodies (immunoparticles). Calprotectin available in the sample mediates immunoparticle agglutination. Sample turbidity, measured by light absorbance, increases with calprotectin-immunoparticle complex formation and is proportional to calprotectin concentration. The detected light absorbance allows quantification of calprotectin concentration via interpolation on an established calibration curve.

", "Language": "en" }, { "Name": "MeasuringRange", "Value": "

Limits and ranges

The measuring range for the fCAL turbo assay on the cobas c 501/502 analyzers is 30‑2000 µg/g. Samples > 2000 µg/g will be diluted automatically (1:10) by the analyzer, further extending the range to 30‑10000 µg/g.

", "Language": "en" }, { "Name": "ExpectedValues", "Value": "

Interpretation of results (clinical thresholds)

Calprotectin concentration

Interpretation

Follow-up

< 80 µg/g

normal

none

80‑160 µg/g

gray-zone/borderline

follow-up within 4‑6 weeks

> 160 µg/g

elevated

repeats as needed

Table 1: fCAL turbo diagnostic ranges

Calprotectin values < 80 μg/g
Fecal calprotectin values < 80 µg/g are not indicative of active inflammation in the gastrointestinal tract. Low fecal calprotectin levels can be used in conjunction with the patient’s clinical symptoms, medical history and other clinical and laboratory findings to determine the need for additional diagnostic work‑up. Specifically, for patients with a clinical and laboratory presentation suggesting a non‑inflammatory disorder such as IBS, fecal calprotectin values of < 80 µg/g can be used to support a decision to defer invasive testing.

Calprotectin values between and equal to 80 and 160 μg/g
Mid‑fecal calprotectin levels between and equal to 80 and 160 µg/g, also called gray‑zone levels, are not directly indicative of an active inflammation requiring immediate follow‑up with invasive testing. However, the presence of inflammation cannot be excluded. Re‑evaluation of fecal calprotectin levels after 4-6 weeks is recommended to determine the inflammatory status. This decision should be made by the clinician in conjunction with the patient’s clinical symptoms, medical history and other clinical and laboratory findings.

Calprotectin values > 160 μg/g
Fecal calprotectin values > 160 µg/g are indicative of neutrophil infiltrate in the gastrointestinal tract; therefore, this may signal the presence of active inflammatory disease. Elevated fecal calprotectin levels can be used in conjunction with the patient’s clinical symptoms, medical history and other clinical and laboratory findings to determine the need for further investigative procedures, including invasive procedures performed by specialists, to achieve an overall clinical diagnosis, in particular of IBD.

", "Language": "en" }, { "Name": "LimitationInterference", "Value": "

Limitations

• Test results should be interpreted in conjunction with information available from clinical assessment of the patient and other diagnostic procedures.
• False negative results could occur in patients who have granulocytopenia due to bone marrow depression.
• Some patients taking non-steroidal anti-inflammatory drugs (NSAID) will have elevations in their fecal calprotectin levels.
• Results may not be clinically applicable to children less than 4 years of age who have mildly increased fecal calprotectin levels.
• Patients with IBD fluctuate between active (inflammatory) and inactive stages of the disease. These stages must be considered when interpreting results of the fecal calprotectin assay.

Special wash programming required by the instrument manufacturer:
The manufacturer of the cobas c systems considers the use of special wash steps as mandatory to avoid carry-over, when certain test combinations are run together.

The latest version of the carry‑over evasion list can be found with the NaOHD-SMS-SmpCln1+2-SCCS Method Sheets provided by the instrument manufacturer. For further instructions refer to the operator’s manual. cobas c 502 analyzer: All special wash programming necessary for avoiding carry‑over is available via the cobas link, manual input is required in certain cases.

Where required, special wash/carry‑over evasion programming must be implemented prior to reporting results with this test.

", "Language": "en" }, { "Name": "OrderInformation", "Value": "

OrderInformation (CC Reagents - cobas + Integra)

Order information

Analyzer(s) on which cobas c pack(s) can be used

08910332190

fCAL turbo (200 tests)

System‑ID 07 7626 2

cobas c 501/502

Materials required (but not provided):

08910499190

fCAL Calibrator Set
fCAL Calibrator 1 (1 x 1 mL)
fCAL Calibrator 2 (1 x 1 mL)
fCAL Calibrator 3 (1 x 1 mL)
fCAL Calibrator 4 (1 x 1 mL)
fCAL Calibrator 5 (1 x 1 mL)
fCAL Calibrator 6 (1 x 1 mL)

Code 719
Code 720
Code 721
Code 722
Code 723
Code 724

08910502190

fCAL Control Set 
fCAL Control Level I  (3 x 1 mL)
fCAL Control Level II  (3 x 1 mL)

08910987001

CALEX® Cap (500 pcs)

", "Language": "en" }, { "Name": "SystemInformation", "Value": "

System information

For cobas c 501 analyzer:

FCAL: ACN 462

For cobas c 502 analyzer:

FCAL: ACN 8462

", "Language": "en" }, { "Name": "Handling", "Value": "

Reagent handling

Ready for use

Loading of reagents

The reagents supplied are ready to use. Mix gently before loading onto the instrument. Avoid bubble formation.

", "Language": "en" }, { "Name": "TestDefinition", "Value": "

Application for fecal extracts

cobas c 501/502 test definition

Assay type

2 Point End

Reaction time / Assay points

10/36‑55

Wavelength (sub/main)

800/546 nm

Reaction direction

Increase

Units

µg/g

Reagent pipetting

Diluent (H2O)

R1

100 µL

R3

20 µL

Sample volumes

Sample

Sample dilution

Sample

Diluent (H2O)

Normal

10 µL

Decreased

10 µL

10 µL

90 µL

Increased

10 µL

Note

For technical reasons it is necessary to specify a dummy unit (µg/mL) on cobas c analyzers. Values can be converted to the correct unit (µg/g) via the host computer.

", "Language": "en" }, { "Name": "StorageStability", "Value": "

Storage and stability

fCAL turbo

Shelf life at 2‑8 °C:

See expiration date on cobas c pack label.

On‑board in use and refrigerated on the analyzer:

store for up to 12 weeks at 5‑12 °C

Do not freeze reagents!

", "Language": "en" }, { "Name": "Calibration", "Value": "

Calibration

Calibrators

S1: fCAL Calibrator 1

S2: fCAL Calibrator 2

S3: fCAL Calibrator 3

S4: fCAL Calibrator 4

S5: fCAL Calibrator 5

S6: fCAL Calibrator 6

Manually configure the calibrators using the codes listed in the \"Order information\" section.

Calibration mode

Spline

Calibration frequency

Full calibration
• after reagent lot change
• after 8 weeks on-board the analyzer
• after 8 weeks when using a single reagent lot
• as required following quality control procedures

To generate a reproducible calibration curve, equilibrate reagents R1 and R3 to the storage temperature of the analyzer by loading the cobas c pack at least 1 hour before calibration curve establishment. Keep calibrators as well as controls and patient samples at room temperature for at least 30 minutes before starting analysis. The calibration on cobas c 501/502 analyzers is performed in duplicate.

Traceability: This method has been standardized against internal reference material.

", "Language": "en" }, { "Name": "Limitations", "Value": "

Clinical evaluation

The ability of the fCAL turbo to discriminate between patients with IBD and other non‑inflammatory gastrointestinal (GI) disorders, including IBS, was evaluated using clinical samples collected from 337 adult and pediatric patients. One hundred and thirty five patients had a final diagnosis of IBD (Crohn’s disease, ulcerative colitis or indeterminate colitis), 130 patients suffered from IBS and 72 patients presented with abdominal pain and/or diarrhea, or other GI‑related non‑inflammatory conditions. Final diagnosis was supported by endoscopic as well as other clinical findings.

Final
diagnosis

Distribution of patients results in numbers (%) within fCAL turbo diagnostic ranges

< 80 μg/g

80‑160 μg/g

> 160 μg/g

Total

IBD

12 (8.9 %)

15 (11.1 %)

108 (80 %)

135 (100 %)

IBS

99 (76.2 %)

15 (11.5 %)

16 (12.3 %)

130 (100 %)

Other GI

51 (70.8 %)

7 (9.7 %)

14 (19.4 %)

72 (100 %)

Table 2: Distributions of patients results within fCAL turbo diagnostic ranges

IBD vs. non‑IBD

Clinical decision point

80 μg/g

160 μg/g

Sensitivity (95 % CI)

91.1 % (85.0 %, 95.3 %)

80.0 % (72.3 %, 86.4 %)

Specificity (95 % CI)

74.3 % (67.7 %, 80.1 %)

85.1 % (79.5 %, 89.8 %)

PPV (95 % CI)

70.3 % (62.9 %, 76.9 %)

78.3 % (70.4 %, 84.8 %)

NPV (95 % CI)

92.6 % (87.4 %, 96.1 %)

86.4 % (80.9 %, 90.9 %)

ROC AUC (95 % CI)

0.916 (0.884, 0.947)

Table 3: Clinical performance characteristics of the fCAL turbo in discriminating IBD from non‑IBD − IBS and other GI‑related disorders, at 80 μg/g and 160 μg/g clinical decision points

IBD vs. IBS

Clinical decision point

80 μg/g

160 μg/g

Sensitivity (95 % CI)

91.1 % (85.0 %, 95.3 %)

80.0 % (72.3 %, 86.4 %)

Specificity (95 % CI)

76.2 % (67.9 %, 83.2 %)

87.7 % (80.8 %, 92.8 %)

PPV (95 % CI)

79.9 % (72.7 %, 85.9 %)

87.1 % (79.9 %, 92.4 %)

NPV (95 % CI)

89.2 % (81.9 %, 94.3 %)

80.9 % (73.4 %, 87.0 %)

ROC AUC (95 % CI)

0.929 (0.898, 0.960)

Table 4: Clinical performance characteristics of the fCAL turbo in discriminating IBD from IBS at 80 μg/g and 160 μg/g clinical decision points

CI − confidence interval
PPV − positive predictive value
NPV − negative predictive value
ROC AUC − area under receiver operating characteristic curve

Reference range

Stool samples were obtained from 141 apparently healthy normal adults (> 21 years of age) with no symptoms or signs of gastrointestinal disease. The test results were categorized by the assay cut‑offs.

Distribution of results within fCAL turbo diagnostic ranges

< 80 μg/g

80-160 μg/g

> 160 μg/g

Total

Number of subjects (%)

106 (75.2 %)

18 (12.8 %)

17 (12.1 %)

141 (100 %)

Table 5: Distribution of healthy subjects results within fCAL turbo diagnostic ranges

", "Language": "en" }, { "Name": "PerformanceData", "Value": "", "Language": "en" }, { "Name": "Precision", "Value": "

Specific performance data

Specific performance data

The presented performance characteristics have been established on a cobas c 501 analyzer. For regulatory purposes validation was performed using extracts obtained by manual weighing and extraction. The CALEX® Cap was validated for comparability with the manual extraction method. Any changes to the directions for use, including special wash programming, may alter the stated performance characteristics of the assay and must be validated prior to implementation by the laboratory. Refer to clinical chemistry analyzer specific application notes for the performance characteristics on other clinical chemistry analyzers.

Method comparison

fCAL turbo vs. BÜHLMANN fCAL® ELISA

The method comparison study was performed according to the CLSI guideline EP09-A3. Two hundred forty‑eight (248) clinical samples were measured according to the instructions for use with the fCAL turbo and with BÜHLMANN fCAL® ELISA assay, with 220 samples yielding results within the measuring range for both tests. Measurements were performed over 18 days using 3 reagent lots.

Bland‑Altman analysis

Passing-Bablok regression
analysis

Mean
bias

(95 % CI)

Lower
LoA

(95 % CI)

Upper
LoA

(95 % CI)

Slope
(95 % CI)

y‑Intercept
(95 % CI)

Bias at 80 μg/g
(95 % CI)

Bias at 160 μg/g
(95 % CI)

r

-0.5 % (-3.6 %, 2.7 %)

-46.5 % (-51.8 %, -41.1 %)

45.5 % (40.2 %, 50.9 %)

1.025 (0.990, 1.058)

-4.5 μg/g (-8.7 μg/g, 0.3 μg/g)

-3.1 %
(-7.2 %, 0.5 %)

-0.3 %
(-2.4 %, 2.7 %)

0.972

Table 6: Method comparison study results, (LoA= Limits of agreement)

CALEX®Cap vs. manual weighing extraction

The method comparison study was performed according to the CLSI guideline EP09-A3. Two hundred forty‑one (241) clinical samples, extracted using the CALEX® Cap and manual weighing and extraction method, were measured according to the instructions for use with the fCAL turbo, with 202 samples yielding results within the measuring range of the assay. Measurements were performed over 18 days using 3 CALEX® Cap lots.

Bland‑Altman analysis

Passing-Bablok regression
analysis

Mean
bias

(95 % CI)

Lower
LoA

(95 % CI)

Upper
LoA

(95 % CI)


Slope
(95 % CI)


y‑Intercept
(95 % CI)

Bias at 80 μg/g
(95 % CI)

Bias at 160 μg/g
(95 % CI)

r

7.7 % (3.5 %, 12.0 %)

-51.9 % (-59.1 %, 44.6 %)

67.4 % (60.1 %, 74.6 %)

1.149 1.100, 1.201)

-8.3 μg/g (-17.1 μg/g, -2.0 μg/g)

4.6 %
(-4.3 %, 9.1 %)

9.7 %
(4.2 %, 13.8 %)

0.921

Table 7: Method comparison study results, (LoA= Limits of agreement)

Reproducibility (multisite precision evaluation study)

Reproducibility was established according to the CLSI guideline EP05-A3 by performing measurements at 3 laboratory sites. Eight pooled stool specimen extracts with calprotectin concentrations covering the measuring range of the test and clinical decision points were tested over 5 days, in 1 run per day, with 5 results generated per run. One reagent lot was used in the study.

ID

Mean [μg/g]

n

Within-run (repeatability)

Between-day

Between-site

Total
precision

SD

% CV

SD

% CV

SD

% CV

SD

% CV

S01

47.2

75

3.6

7.6 %

2.4

5.0 %

0.0

0.0 %

4.3

9.1 %

S02

91.1

75

3.5

3.8 %

3.5

3.8 %

2.8

3.1 %

5.7

6.2 %

S03

185.4

75

5.1

2.7 %

2.7

1.4 %

5.5

3.0 %

7.9

4.3 %

S04

276.9

75

6.4

2.3 %

4.5

1.6 %

9.7

3.5 %

12.5

4.5 %

S05

674.5

75

12.9

1.9 %

1.2

0.2 %

22.8

3.4 %

26.3

3.9 %

S06

1519.6

75

25.3

1.7 %

17.8

1.2 %

62.3

4.1 %

69.6

4.6 %

S07

3343.8

75

54.6

1.6 %

35.6

1.1 %

100.0

3.0 %

119.4

3.6 %

S08

5475.6

75

72.1

1.3 %

35.8

0.7 %

154.2

2.8 %

173.9

3.2 %

Table 8: Reproducibility study results – within‑run, between‑day, between‑site and total precision estimates

Between‑lot precision

Between‑lot precision was established according to the CLSI guideline EP05-A3. Eight pooled stool extracts with calprotectin concentrations covering the measuring range of the test and clinical decision points were tested over 5 days, in 1 run per day, with 5 results generated per run. Three reagent lots were used in the study.

ID

Mean [μg/g]

n

Within-run (repeatability)

Between-day

Between-lot

Total
precision

SD

% CV

SD

% CV

SD

% CV

SD

% CV

S01

45.2

75

3.2

7.1 %

1.4

3.0 %

3.7

8.2 %

5.1

11.3 %

S02

86.4

75

3.7

4.3 %

1.2

1.4 %

5.7

6.6 %

6.9

7.9 %

S03

175.8

75

5.0

2.9 %

0.3

0.2 %

9.9

5.6 %

11.1

6.3 %

S04

263.9

75

7.6

2.9 %

0.0

0.0 %

10.0

3.8 %

12.5

4.7 %

S05

647.4

75

15.5

2.4 %

0.0

0.0 %

15.3

2.4 %

21.7

3.4 %

S06

1460.7

75

33.7

2.3 %

11.6

0.8 %

41.0

2.8 %

54.3

3.7 %

S07

3234.5

75

71.2

2.2 %

8.9

0.3 %

130.3

4.0 %

148.8

4.6 %

S08

5303.1

75

97.4

1.8 %

11.2

0.2 %

163.9

3.1 %

191.0

3.6 %

Table 9: Between‑lot precision study results

Within-laboratory precision

Repeatability and within‑laboratory precision were established according to the CLSI guideline EP05-A3. Eight pooled stool specimen extracts with calprotectin concentrations covering the measuring range of the test and clinical decision points were tested over 20 days, in 2 runs per day, with 2 results generated per run. One reagent lot was used in the study.

ID

Mean [μg/g]

n

Repeatability

Between-run

Between-day

Within-laboratory

SD

% CV

SD

% CV

SD

% CV

SD

% CV

S01

42.9

80

3.6

8.3 %

1.2

2.7 %

1.1

2.5 %

3.9

9.1 %

S02

98.4

80

2.5

2.6 %

1.8

1.8 %

2.2

2.2 %

3.7

3.8 %

S03

166.5

80

4.3

2.6 %

0.8

0.5 %

1.9

1.2 %

4.8

2.9 %

S04

267.6

80

3.9

1.4 %

2.5

0.9 %

1.8

0.7 %

5.0

1.9 %

S05

642.0

80

20.1

3.1 %

14.9

2.3 %

0.0

0.0 %

25.1

3.9 %

S06

1414.2

80

19.6

1.4 %

11.1

0.8 %

3.5

0.2 %

22.8

1.6 %

S07

3251.4

80

40.8

1.3 %

21.4

0.7 %

19.7

0.6 %

50.1

1.5 %

S08

5405.6

80

40.2

0.7 %

56.6

1.0 %

34.5

0.6 %

77.5

1.4 %

Table 10: Within‑laboratory precision study results

Extraction reproducibility ‑ CALEX®Cap

The extraction reproducibility was established according to the CLSI guideline EP05‑A3. Twelve clinical stool specimens, selected to reflect different stool consistencies: solid, semi-solid and liquid, with calprotectin concentrations covering the measuring range of the test and clinical decision points, were extracted in duplicate by 2 operators on 2 days using 3 CALEX® Cap lots. Each stool extract was tested in 3 replicates using 1 reagent lot of the fCAL turbo.

ID

Mean [µg/g]

n

Within-run

Between-extraction

Between-day

SD

% CV

SD

% CV

SD

% CV

S1

42.7

72

3.2

7.5

4.6

10.8

0.0

0.0

S2

71.5

72

3.9

5.4

6.9

9.6

9.4

13.1

S3

111.3

72

3.3

2.9

14.2

12.7

0.0

0.0

S4

119.8

72

2.9

2.4

7.2

6.0

5.8

4.8

S5

213.0

72

3.2

1.5

27.9

13.1

0.0

0.0

S6

297.2

72

3.7

1.2

24.5

8.2

13.5

4.6

S7

561.2

72

5.5

1.0

18.6

3.3

66.1

11.8

S8

610.0

72

4.7

0.8

74.3

12.2

28.2

4.6

S9

940.4

72

12.2

1.3

152.7

16.2

34.8

3.7

S10

1558.4

72

7.8

0.5

152.0

9.8

39.9

2.6

S11

2041.6

72

27.2

1.3

150.3

7.4

133.8

6.6

S12

3440.0

72

48.7

1.4

177.7

5.2

321.5

9.3

ID

Mean [µg/g]

n

Between-lot

Between-operator

Total precision

SD

% CV

SD

% CV

SD

% CV

S1

42.7

72

2.7

6.3

0.0

0.0

6.2

14.5

S2

71.5

72

0.0

0.0

0.0

0.0

12.2

17.1

S3

111.3

72

6.8

6.1

7.8

7.0

17.9

16.1

S4

119.8

72

0.0

0.0

0.0

0.0

9.7

8.1

S5

213.0

72

0.0

0.0

9.0

4.2

29.5

13.8

S6

297.2

72

18.0

6.1

12.3

4.1

35.6

12.0

S7

561.2

72

0.0

0.0

0.0

0.0

68.9

12.3

S8

610.0

72

0.0

0.0

0.0

0.0

79.6

13.1

S9

940.4

72

0.0

0.0

97.5

10.4

184.9

19.7

S10

1558.4

72

98.6

6.3

146.2

9.4

236.4

15.2

S11

2041.6

72

88.9

4.4

10.5

0.5

221.9

10.9

S12

3440.0

72

0.0

0.0

0.0

0.0

370.5

10.8

Table 11: CALEX® Cap extraction reproducibility study results

", "Language": "en" }, { "Name": "MethodComparison", "Value": "", "Language": "en" }, { "Name": "Summary", "Value": "

Summary

Gastroenterologists are often faced with the diagnostic difficulty of differentiating individuals with functional gastrointestinal disorders, such as irritable bowel syndrome (IBS), from those with inflammatory bowel disease (IBD). Many symptoms are common to both conditions, whereas other clinical features such as a predominance of diarrhea and rectal bleeding will increase the likelihood of inflammatory disease. The clinical differentiation between these conditions remains problematic and may result in delayed diagnosis. Furthermore, many individuals with IBS must undergo invasive procedures (endoscopy) to rule out an organic disorder. This has significant implications for health care costs as well as exposing individuals to the inherent risks associated with invasive procedures.

LREFOcchipinti K, Smith JW. Clin Colon Rectal Surg 2012;25(1):46-52
,
LREFPavlidis P, Chedgy FJ, Tibble JA Scand J Gastroenterol. 2013;48(9):1048-54.
,
LREFMindemark M, Larsson A. Clin Biochem. 2012;45(7-8):552-5
,
LREFWaugh N, Cummins E, Royle P et al. Health Technol Assess. 2013;17(55):xv-xix, 1-211
Diseases included in the IBD category include Crohn´s disease (CD), ulcerative colitis (UC) and indeterminate colitis. IBD represents chronic and often disabling lifelong inflammatory conditions – frequently diagnosed in young people in their late teens and early twenties. It is estimated that nearly 1.2 million Americans are living with IBD, and the prevalence is rising.
LREFKappelman MD, Moore KR, Allen JK et al. Dig Dis Sci. 2013;58(2):519-25
The main difference between CD and UC is the location and nature of the inflammatory condition. In UC, the disease is restricted to the colon, whereas in CD, inflammation may affect any part of the gastrointestinal tract – the ileo-cecal area being most often affected.
LREFStange EF, Travis SP, Vermeire S et al. J Crohns Colitis 2008;2(1):1-23
,
LREFVan Assche G, Dignass A, Panes J et al. J Crohns Colitis 2010;4(1):7-27
The most striking difference between IBS and IBD is that the former is non-inflammatory in nature. Therefore, one possibility is to measure surrogate markers of intestinal inflammation to differentiate between the two.
LREFTibble JA, Sigthorsson G, Foster R et al. Gastroenterol 2002;123(2):450-460.
,
LREFJahnsen J, Røseth AG, Aadland E. Tidsskr Nor Laegeforen 2008;128:743-5
Calprotectin is a calcium-binding protein found in neutrophilic granulocytes, monocytes, and macrophages, comprises up to 60 % of the total cytosolic protein content of neutrophils, resists metabolic degradation, and can be measured in feces.
LREFDale I, Brandtzaeg P, Fagerhol MK et al. Am J Clin Pathol 1985;84(1):24-34
,
LREFRøseth AG, Aadland E, Jahnsen J et al. Digestion 1997;58(2):176-180
,
LREFRøseth AG, Fagerhol MK, Aadland E et al. Scand J Gastroenterol 1992;27(9):793-798
Its use as a biomarker of intestinal inflammation has been extensively validated, showing consistently abnormal levels in the stool of individuals with IBD.
LREFFagerhol MK. Lancet 2000;356(9244):1783-4
,
LREFKonikoff MR, Denson LA. Inflamm Bowel Dis. 2006;12(6):524-34.
,
LREFVan Rheenen PF, Van de Vijver E, Fidler V. BMJ 2010;341:c3369. doi: 10.1136/bmj.c3369.
,
LREFBurri E, Beglinger C. Swiss Med Wkly 2012;142:w13557. doi: 10.4414/smw.2012.13557. eCollection 2012.

", "Language": "en" }, { "Name": "Reagents", "Value": "

Reagents - working solutions

Reagents

Quantity

Preparation

Reaction Buffer (R1)
MOPS buffered saline

23.0 mL

Ready to use

Immunoparticles (R3)
Polystyrene beads coated with avian antibodies against human calprotectin

6.6 mL

Ready to use

R1 is in position B and R3 is in position C. R3 refers to the reagent, which is pipetted at time point R3.

", "Language": "en" }, { "Name": "PrecautionsWarnings", "Value": "

Precautions and warnings

For in vitro diagnostic use.
Exercise the normal precautions required for handling all laboratory reagents.
Disposal of all waste material should be in accordance with local guidelines.
Safety data sheet available for professional user on request.

Product safety labeling follows GHS guidance.

Contact phone: 1-800-428-2336

• This kit contains 2-methyl-4-isothiazolin-3-one hydrochloride (conc. ≥ 0.0015 %), thus the reagents may cause allergic skin reactions (H317).
• The immunoparticles contain potentially infectious substances of animal origin and should be handled in accordance with good laboratory practice (GLP) using appropriate precautions.
• R1 contains MOPS (3-(N-morpholino)propanesulfonic acid) (< 1 %), that can be irritating to eyes and skin. Handle with due caution.
• Avoid contact of reagents with the skin, eyes or mucous membranes. If contact does occur, immediately wash with generous amounts of water; otherwise, irritation / burns can occur.
• Immunoparticles R3 contains polystyrene nanoparticles.
• Reagent Immunoparticles R3, once frozen, cannot be used anymore. Freezing R3 will lead to reduced sensitivity and precision in low‑level samples and in the worst case to decreased measurement levels.
• The assay is designed for fecal extract samples prepared using the specific CALEX® Cap. Application of other extraction buffers could lead to incorrect results.
• Please equilibrate reagents, controls, calibrators and samples as described in this method sheet.
• Ensure that samples have no bubbles prior to running the test.
• Evaporation of calibrators and controls on the analyzer could lead to incorrect results. Run the assay immediately after loading the analyzer.

", "Language": "en" }, { "Name": "Caution", "Value": "", "Language": "en" }, { "Name": "QualityControl", "Value": "

Quality control

For quality control, use control materials as listed in the \"Order information\" section.

Manually configure QC material using non-Roche QC material codes.

Validating instrument accuracy after calibration

Run the fCAL Control Set, Level I and Level II, in duplicate, after each new calibration, before running patient fecal sample extracts. Keep controls at room temperature for at least 30 minutes before starting analysis.

Validating daily runs

Run the fCAL Control Set, Level I and Level II, each day, before running patient fecal sample extracts to validate calibration curve stability. Single measurements of controls are sufficient.

The controls have assigned target values indicated on the control value sheet supplied with each lot of the fCAL Control Set. All control measurements must be within target values indicated on the control value sheet to obtain valid results for patient fecal sample extracts. If the control values are not valid, repeat quality control measurement with fresh controls. If control values remain invalid, recalibrate the instrument. If valid control values cannot be reproduced, after performing the steps described above, contact Roche US Technical Support 1-800-428-2336.

Measuring patient samples

Once a calibration curve is established and validated with the quality controls, patient fecal extracts may be measured. Allow patient fecal sample extracts to equilibrate to room temperature for at least 30 minutes before starting analysis. Perform patient fecal extract measurement according to this instruction for use and the instrument manual.

", "Language": "en" }, { "Name": "SpecimenPreparation", "Value": "

Specimen collection and preparation

The fCAL turbo is designed for calprotectin quantification in fecal sample extracts. Fecal samples are collected, extracted and diluted to a final concentration of 1:500 using the CALEX® Cap.

Specimen transport and storage

Stool specimens should be received for processing by the laboratory within 3 days of collection. Stool specimens may be shipped at room temperature or refrigerated. Stool specimens should be refrigerated at 2-8 °C and extracted within 3 days of receipt at the laboratory. Do not store samples at elevated temperatures.

Stool sample extraction and extract stability

Follow the instruction for use provided with the CALEX® Cap. Fecal sample extracts prepared using the CALEX® Cap will have a final dilution of 1:500 and are ready to use. Liquid stool samples can be pipetted directly into the CALEX® Cap. Unscrew the blue cap and pipet 10 μL of stool sample into the device. Recap the CALEX® Cap and proceed with vortexing step according to the extraction procedure described and illustrated in the instruction for use delivered with the CALEX® Cap.

Important: Centrifuge the CALEX® Cap for 10 minutes at 1000‑3000 g prior to running the fCAL turbo procedure.

CALEX® Cap extracts can be kept at room temperature for up to 2 hours, and after centrifugation, at 2-8 °C for up to 3.5 days (84 hours). For longer storage, freeze CALEX® Cap extracts at -20 °C. CALEX® Cap extracts can be subjected to 4 freeze-thaw cycles. Allow frozen extracts to equilibrate to room temperature for up to 2 hours before measurement. Prior to measurement, CALEX® Cap extract should be vortexed thoroughly for 10 seconds and centrifuged for 10 minutes at 1000‑3000 g.

Please note that extracts can be stored and frozen directly within the CALEX® Cap.

", "Language": "en" } ] } } ] }

FCAL

fCAL turbo

IVD For in vitro diagnostic use.

Overview

Detailed Specifications

Ordering Information

Compatible Instruments

...
    ...

    Technical Documents

    Access Material Data Sheets, Certificates of Analysis, and other product documentation.

    After clicking below, you will be redirected to eLabDoc, where you can choose your local country.